U.S. patent application number 15/880354 was filed with the patent office on 2018-07-19 for targeted integration into the ppp1r12c locus.
The applicant listed for this patent is Sangamo Therapeutics, Inc.. Invention is credited to Russell DeKelver, Philip D. Gregory, David Paschon, Philip Tam, Fyodor Urnov.
Application Number | 20180201955 15/880354 |
Document ID | / |
Family ID | 39926269 |
Filed Date | 2018-07-19 |
United States Patent
Application |
20180201955 |
Kind Code |
A1 |
DeKelver; Russell ; et
al. |
July 19, 2018 |
TARGETED INTEGRATION INTO THE PPP1R12C LOCUS
Abstract
Disclosed herein are methods and compositions for targeted
integration of an exogenous sequence into the human PPP1R12C locus,
for example, for expression of a polypeptide of interest.
Inventors: |
DeKelver; Russell;
(Richmond, CA) ; Gregory; Philip D.; (Richmond,
CA) ; Paschon; David; (Richmond, CA) ; Tam;
Philip; (Richmond, CA) ; Urnov; Fyodor;
(Richmond, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Sangamo Therapeutics, Inc. |
Richmond |
CA |
US |
|
|
Family ID: |
39926269 |
Appl. No.: |
15/880354 |
Filed: |
January 25, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15014372 |
Feb 3, 2016 |
9914940 |
|
|
15880354 |
|
|
|
|
14447378 |
Jul 30, 2014 |
9267154 |
|
|
15014372 |
|
|
|
|
13341228 |
Dec 30, 2011 |
8822221 |
|
|
14447378 |
|
|
|
|
12150103 |
Apr 24, 2008 |
8110379 |
|
|
13341228 |
|
|
|
|
60926322 |
Apr 26, 2007 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N 15/907 20130101;
C12N 2800/30 20130101; C07K 14/43595 20130101; C07K 14/435
20130101; C12N 15/113 20130101; A61P 43/00 20180101; C07K 2319/81
20130101; C12N 15/1082 20130101; C12N 9/22 20130101; C12Y 301/21004
20130101; C12N 2800/10 20130101 |
International
Class: |
C12N 15/90 20060101
C12N015/90; C12N 15/10 20060101 C12N015/10; C07K 14/435 20060101
C07K014/435; C12N 9/22 20060101 C12N009/22; C12N 15/113 20060101
C12N015/113 |
Claims
1. A method for expressing a protein in a cell of a subject, the
method comprising: introducing into the subject (a) a donor
sequence comprising a transgene encoding the protein and (b) one or
more polynucleotides encoding one or more nucleases, each nuclease
comprising (i) a DNA-binding domain and (ii) a cleavage domain or
cleavage half-domain, wherein the DNA-binding domain has been
engineered to bind to a first target site in intron 1 of a PPP1R12C
gene in the genome of a cell; such that following cleavage of the
PPP1R12C gene, the transgene is integrated into and expressed from
the PPP1R12C gene.
2. The method of claim 1, wherein the one or more polynucleotides
encode at least two nucleases.
3. The method of claim 1, wherein the donor sequence and/or one or
more polynucleotides are carried on viral or non-viral vectors.
4. The method of claim 3, wherein the donor sequence is carried on
a viral vector.
5. The method of claim 1, wherein the transgene is selected from
the group consisting of an antibody, an antigen, an enzyme, a
growth factor, a cell surface receptor, a nuclear receptor, a
hormone, a lymphokine, a cytokine, a reporter, functional fragments
thereof and combinations thereof.
6. The method of claim 1, wherein the donor sequence comprises a
promoter that drives expression of the transgene.
7. The method of claim 1, wherein the donor sequence does not
comprise a promoter and expression of the transgene is driven by an
endogenous promoter.
8. The method of claim 3, wherein the donor sequence further
comprises a first nucleotide sequence that is homologous but
non-identical to a first sequence in the PPP1R12C gene.
9. The method of claim 8, wherein the donor sequence further
comprises a second nucleotide sequence that is homologous but
non-identical to a second sequence in the PPP1R12C gene.
10. The method of claim 8, wherein the donor sequence comprises a
tandem cassette.
11. The method of claim 1, wherein the donor sequence is a
plasmid.
12. The method of claim 1, wherein the donor sequence is a linear
DNA molecule.
13. The method of claim 1, wherein the cleavage half-domains are
from a Type IIS restriction endonuclease.
14. The method of claim 13, wherein the Type IIS restriction
endonuclease is selected from the group consisting of FokI and
StsI.
15. The method of claim 1, wherein at least one of the cleavage
half-domains comprises an alteration in the amino acid sequence of
a dimerization interface of the cleavage half-domain.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of U.S. patent
application Ser. No. 15/014,372, filed Feb. 3, 2016, which is a
continuation of U.S. patent application Ser. No. 14/447,378, filed
Jul. 30, 2014, now U.S. Pat. No. 9,267,154 which is a continuation
of U.S. patent application Ser. No. 13/341,228, filed Dec. 30, 2011
now U.S. Pat. No. 8,822,221, which is a continuation of U.S. patent
application Ser. No. 12/150,103, filed Apr. 24, 2008, now U.S. Pat.
No. 8,110,379, which claims the benefit of U.S. Provisional
Application No. 60/926,322, filed Apr. 26, 2007, the disclosures of
which are hereby incorporated by reference in their entireties.
STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED
RESEARCH
[0002] Not applicable.
TECHNICAL FIELD
[0003] The present disclosure is in the field of genome
engineering, particularly targeted integration into the human
PPP1R12C ("p84" or "AAVS1") gene.
BACKGROUND
[0004] A major area of interest in genome biology, especially in
light of the determination of the complete nucleotide sequences of
a number of genomes, is targeted integration of one or more
sequences of interest into desired locations. Attempts have been
made to alter genomic sequences in cultured cells by taking
advantage of the natural phenomenon of homologous recombination.
See, for example, Capecchi (1989) Science 244:1288-1292; U.S. Pat.
Nos. 6,528,313 and 6,528,314. If a polynucleotide has sufficient
homology to the genomic region containing the sequence to be
altered, it is possible for part or all of the sequence of the
polynucleotide to replace the genomic sequence by homologous
recombination. However, the frequency of homologous recombination
under these circumstances is extremely low. Moreover, the frequency
of insertion of the exogenous polynucleotide at genomic locations
that lack sequence homology exceeds the frequency of targeted
homologous recombination by several orders of magnitude. Sedivy and
Joyner (1992) Gene Targeting, Oxford University Press, Oxford.
[0005] The introduction of a double-stranded break into genomic
DNA, in the region of the genome bearing homology to an exogenous
polynucleotide, has been shown to stimulate homologous
recombination at this site by several thousand-fold in cultured
cells. Rouet et al. (1994) Mol. Cell. Biol. 14:8096-8106; Choulika
et al. (1995) Mol. Cell. Biol. 15:1968-1973; Donoho et al.
(1998)Mol. Cell. Biol. 18:4070-4078. See also Johnson et al. (2001)
Biochem. Soc. Trans. 29:196-201; and Yanez et al. (1998) Gene
Therapy 5:149-159. In these methods, DNA cleavage in the desired
genomic region was accomplished by inserting a recognition site for
a meganuclease (i.e., an endonuclease whose recognition sequence is
so large that it does not occur, or occurs only rarely, in the
genome of interest) into the desired genomic region.
[0006] Various methods and compositions for targeted cleavage of
genomic DNA have been described. Such targeted cleavage events can
be used, for example, to induce targeted mutagenesis, induce
targeted deletions of cellular DNA sequences, and facilitate
targeted recombination at a predetermined chromosomal locus. See,
for example, U.S. Patent Publication Nos. 2003/0232410;
2005/0208489; 2005/0026157; 2005/0064474; and 2006/0188987, and
International Patent Publication No. WO 2007/014275, the
disclosures of which are incorporated by reference in their
entireties for all purposes.
[0007] However, there remain needs for compositions and methods for
stable targeted integration into a safe harbor locus within the
genome, in particular, the non-essential endogenous PPP1R12C (also
known as p84 and/or AAVS1) gene locus.
SUMMARY
[0008] The present disclosure provides method and compositions for
expressing one or more products of an exogenous nucleic acid
sequence (i.e. a protein or a RNA molecule) that has been
integrated into the PPP1R12C gene in a cell. The exogenous nucleic
acid sequence can comprise, for example, one or more genes or cDNA
molecules, or any type of coding or noncoding sequence, as well as
one or more control elements (e.g., promoters). In addition, the
exogenous nucleic acid sequence may produce one or more RNA
molecules (e.g., small hairpin RNAs (shRNAs), inhibitory RNAs
(RNAis), microRNAs (miRNAs), etc.). The exogenous nucleic acid
sequence is introduced into the cell such that it is integrated
into the genome of the cell in the PPP1R12C gene, which lies on
chromosome 19.
[0009] Integration of the exogenous nucleic acid sequence into the
PPP1R12C gene is facilitated by targeted double-strand cleavage of
the genome in the PPP1R12C gene. Cleavage is targeted to the
PPP1R12C gene through the use of fusion proteins comprising a zinc
finger DNA binding domain, which is engineered to bind a sequence
within PPP1R12C, and a cleavage domain or a cleavage half-domain.
Such cleavage stimulates integration of exogenous polynucleotide
sequences at or near the cleavage site. Integration of exogenous
sequences can proceed through both homology-dependent and
homology-independent mechanisms.
[0010] In one aspect, disclosed herein are engineered zinc finger
proteins that bind to a target site in the PPP1R12C gene, for
example, any of the engineered zinc finger proteins comprising the
recognition helices shown in Table 1. In certain embodiments, the
engineered zinc finger protein comprises four zinc fingers
designated F1 to F4 from N-terminus to C-terminus and wherein F1-F4
comprise the following sequences: F1: YNWHLQR (SEQ ID NO:16); F2:
RSDHLTT (SEQ ID NO:8); F3: HNYARDC (SEQ ID NO:9); and F4: QNSTRIG
(SEQ ID NO:15). In other embodiments, the engineered zinc finger
protein comprises four zinc fingers designated F1 to F4 and where
F1 comprises QSSNLAR (SEQ ID NO:3); F2 comprises RTDYLVD (SEQ ID
NO:11); F3 comprises YNTHLTR (SEQ ID NO:12); and F4 comprises
QGYNLAG (SEQ ID NO:13). In still further embodiments, the
disclosure includes engineered zinc finger proteins including 2 or
3 zinc fingers having the recognition helices of a ZFN shown in
Table 1. For example, provided herein are engineered zinc finger
proteins comprising four zinc fingers designated F1 to F4 from
N-terminus to C-terminus, wherein the proteins comprise F1, F2 and
F3; or F1, F3, F4; or F1, F2, F4; or F2, F3 and F4; or F1 and F2;
or F1 and F3; or F1 and F4; or F2 and F3; or F2 and F4; or F3 and
F4 of any of the ZFNs shown in Table 1 and wherein the remaining
fingers comprise sequences that differ from the individual finger
sequences shown in Table 1. Any of the zinc finger proteins
described herein may further comprise a functional domain, for
example a cleavage domain or cleavage half-domain (e.g., the
cleavage half-domain is from a Type IIS restriction endonuclease
such as FokI or StsI).
[0011] In another aspect, disclosed herein is a method for
expressing the product of an exogenous nucleic acid sequence in a
cell, the method comprising: (a) expressing a first fusion protein
in the cell, the first fusion protein comprising a first zinc
finger binding domain and a first cleavage half-domain, wherein the
first zinc finger binding domain has been engineered to bind to a
first target site in the PPP1R12C gene of the genome of the cell;
(b) expressing a second fusion protein in the cell, the second
fusion protein comprising a second zinc finger binding domain and a
second cleavage half domain, wherein the second zinc finger binding
domain binds to a second target site in the PPP1R12C gene of the
genome of the cell, wherein the second target site is different
from the first target site; and (c) contacting the cell with a
polynucleotide comprising an exogenous nucleic acid sequence and a
first nucleotide sequence that is homologous to a first sequence in
the PPP1R12C gene; wherein binding of the first fusion protein to
the first target site, and binding of the second fusion protein to
the second target site, positions the cleavage half-domains such
that the genome of the cell is cleaved in the PPP1R12C gene,
thereby resulting in integration of the exogenous sequence into the
genome of the cell in the PPP1R12C gene and expression of the
product of the exogenous sequence.
[0012] The exogenous nucleic acid sequence may comprise a sequence
encoding one or more functional polypeptides (e.g., a cDNA), with
or without one or more promoters and/or may produce one or more RNA
sequences (e.g., via one or more shRNA expression cassettes). In
certain embodiments, the nucleic acid sequence comprises a
promoterless sequence encoding an antibody, an antigen, an enzyme,
a growth factor, a receptor (cell surface or nuclear), a hormone, a
lymphokine, a cytokine, a reporter, functional fragments of any of
the above and combinations of the above. Expression of the
integrated sequence is then ensured by transcription driven by the
endogenous PPP1R12C promoter. In other embodiments, a "tandem"
cassette is integrated into the PPP1R12C locus in this manner, the
first component of the cassette comprising a promotorless sequence
as described above, followed by a transcription termination
sequence, and a second sequence, encoding an autonomous expression
cassette.
[0013] In certain embodiments, the polynucleotide further comprises
a second nucleotide sequence that is homologous to a second
sequence in the PPP1R12C gene. The second nucleotide sequence may
be identical to the second sequence in the PPP1R12C gene.
Furthermore, in embodiments comprising first and second nucleotide
sequences, the first nucleotide sequence may be identical to the
first sequence in the PPP1R12C gene and the second nucleotide
sequence may be homologous but non-identical to a second sequence
in the PPP1R12C gene. In any of the methods described herein, the
first and second nucleotide sequences flank the exogenous
sequence.
[0014] In certain embodiments, the polynucleotide is a plasmid. In
other embodiments, the polynucleotide is a linear DNA molecule.
[0015] In another aspect, provided herein is a method for
integrating an exogenous sequence into the PPP1R12C gene in the
genome of a cell, the method comprising: (a) expressing a first
fusion protein in the cell, the first fusion protein comprising a
first zinc finger binding domain and a first cleavage half-domain,
wherein the first zinc finger binding domain has been engineered to
bind to a first target site in the PPP1R12C locus in the genome of
the cell; (b) expressing a second fusion protein in the cell, the
second fusion protein comprising a second zinc finger binding
domain and a second cleavage half domain, wherein the second zinc
finger binding domain binds to a second target site in the PPP1R12C
locus in the genome of the cell, wherein the second target site is
different from the first target site; and (c) contacting the cell
with a polynucleotide comprising an exogenous nucleic acid
sequence; wherein binding of the first fusion protein to the first
target site, and binding of the second fusion protein to the second
target site, positions the cleavage half-domains such that the
genome of the cell is cleaved in the PPP1R12C locus, thereby
resulting in homology dependent integration of the exogenous
sequence into the genome of the cell within the PPP1R12C locus. In
certain embodiments, an exogenous sequence encoding a functional
polypeptide is inserted into the PPP1R12C gene.
[0016] In any of the methods described herein, the first and second
cleavage half-domains are from a Type IIS restriction endonuclease,
for example, FokI or StsI. Furthermore, in any of the methods
described herein, at least one of the fusion proteins may comprise
an alteration in the amino acid sequence of the dimerization
interface of the cleavage half-domain, for example such that
obligate heterodimers of the cleavage half-domains are formed.
[0017] In any of the methods described herein, the cell can be a
mammalian cell, for example, a human cell. Furthermore, the cell
may be arrested in the G2 phase of the cell cycle. In addition, in
any of the methods described herein, the first and/or second zinc
finger binding domain may comprise a zinc finger protein having the
recognition helices set forth in Table 1 (e.g., methods in which
the pair of ZFNs used comprises ZFN 15556 and ZFN 15590).
[0018] The present subject matter thus includes, but is not limited
to, the following embodiments:
[0019] 1. A method for expressing the product of an exogenous
nucleic acid sequence in a cell, the method comprising:
[0020] (a) expressing a first fusion protein in the cell, the first
fusion protein comprising a first zinc finger binding domain and a
first cleavage half-domain, wherein the first zinc finger binding
domain has been engineered to bind to a first target site in the
PPP1R12C gene in the genome of the cell;
[0021] (b) expressing a second fusion protein in the cell, the
second fusion protein comprising a second zinc finger binding
domain and a second cleavage half domain, wherein the second zinc
finger binding domain binds to a second target site in the PPP1R12C
gene in the genome of the cell, wherein the second target site is
different from the first target site; and
[0022] (c) contacting the cell with a polynucleotide comprising an
exogenous nucleic acid sequence;
[0023] wherein binding of the first fusion protein to the first
target site, and binding of the second fusion protein to the second
target site, positions the cleavage half-domains such that the
genome of the cell is cleaved in the PPP1R12C gene, thereby
resulting in the homology dependent integration of the exogenous
sequence into the genome of the cell in the PPP1R12C gene and
expression of the product of the exogenous sequence.
[0024] 2. The method according to 1, wherein the exogenous nucleic
acid sequence encodes a polypeptide.
[0025] 3. The method according to 2, wherein the polypeptide is
selected from the group consisting of an antibody, an antigen, an
enzyme, a growth factor, a receptor (cell surface or nuclear), a
hormone, a lymphokine, a cytokine, a reporter, functional fragments
thereof and combinations thereof
[0026] 4. The method according to any of 1 to 3, wherein the
exogenous sequence further comprises a promoter.
[0027] 5. The method according to 4, wherein the polynucleotide
further comprises a first nucleotide sequence that is homologous
but non-identical to a first sequence in the PPP1R12C gene.
[0028] 6. The method according to 5, wherein the polynucleotide
further comprises a second nucleotide sequence that is homologous
but non-identical to a second sequence in the PPP1R12C gene.
[0029] 7. The method according to 6, wherein the first and second
nucleotide sequences flank the exogenous sequence.
[0030] 8. The method of any of any of 1 to 7, wherein the
polynucleotide is a plasmid.
[0031] 9. The method of 1, wherein the polynucleotide is a linear
DNA molecule.
[0032] 10. The method according to any of 1 to 9, wherein the first
and second cleavage half-domains are from a Type IIS restriction
endonuclease.
[0033] 11. The method according to 10, wherein the Type IIS
restriction endonuclease is selected from the group consisting of
FokI and StsI.
[0034] 12. The method according to any of 1 to 12, wherein the cell
is arrested in the G2 phase of the cell cycle.
[0035] 13. The method according to any of 1 to 11, wherein at least
one of the fusion proteins comprises an alteration in the amino
acid sequence of the dimerization interface of the cleavage
half-domain.
[0036] 14. The method according to 1 to 13, wherein the cell is a
mammalian cell.
[0037] 15. The method according to 14, wherein the cell is a human
cell.
BRIEF DESCRIPTION OF THE DRAWINGS
[0038] FIG. 1 is a schematic depicting various polynucleotide
components involved in zinc finger nuclease (ZFN)-driven targeted
insertion into the PPP1R12C gene. See, Example 1. The top line
depicts the endogenous PPP1R12C locus, including an exemplary ZFN
target site and region of homology to an exemplary plasmid donor
encoding GFP. The middle line depicts a circular GFP plasmid donor.
In the presence of the ZFN, the GFP coding sequence carried on the
plasmid donor is inserted into the PPP1R12C gene as shown in the
bottom schematic. The embodiment displayed in the figure allows for
the transcription of the integrated GFP open reading frame and its
subsequent translation by the integration of a splice acceptor (SA)
site, followed by a translation interruption-reinitiation signal
(2A; Fang et al. (2005) Nat Biotech. 23:584), followed by the GFP
open reading frame, and a polyadenylation signal.
[0039] FIG. 2 schematically depicts chromosome 19 (top line) and
the locations of PPP1R12C/p84 within chromosome 19 (middle line).
An exemplary ZFN binding site is shown on the bottom line in intron
1 of PPP1R12C.
[0040] FIGS. 3A through 3C depict targeted integration assays
evaluating GFP ORF integration in cells transfected with the donor
polynucleotide shown in FIG. 1 alone (lane labeled "donor only") or
with the donor polynucleotide and PPP1R12C-targeted ZFNs (lane
labeled "donor+ZFN"). FIG. 3A shows results in K562 cells; FIG. 3B
shows results in 293T cells; and FIG. 3C shows results in Hep3B
cells.
[0041] FIGS. 4A through 4F depict the percentage of GFP-positive
cells as evaluated by FACS. FIG. 4A depicts GFP-positive cells in
K562 cells transfected with the GFP-donor only. FIG. 4B depicts
GFP-positive cells in K562 cells transfected with the GFP-donor and
PPP1R12C-targeted ZFNs. FIG. 4C depicts GFP-positive cells in 293T
cells transfected with the GFP-donor only. FIG. 4D depicts
GFP-positive cells in 293T cells transfected with the GFP-donor and
PPP1R12C-targeted ZFNs. FIG. 4E depicts GFP-positive cells in Hep3B
cells transfected with the GFP-donor only. FIG. 4F depicts
GFP-positive cells in Hep3B cells transfected with the GFP-donor
and PPP1R12C-targeted ZFNs.
[0042] FIG. 5 is a graph depicting expression of PPP1R12C/p84 mRNA
in the indicated cell types. PPP1R12C/18S indicates expression of
the PPP1R12C locus relative to 18S, while PPP1R12C/GAPDH indicates
expression relative to expression of GAPDH.
[0043] FIG. 6 depicts integration of a donor polynucleotide into
the PPP1R12C/p84 locus in the presence or absence of the indicated
ZFNs. The percent integration is shown beneath each lane. Lane 1
shows the negative control (no ZFN). Lane 2 shows cells tranfected
with ZFN pair 15554/15587; lane 3 shows cells transfected with ZFN
pair 15554/15590; lane 4 shows cells transfected with ZFN pair
15556/15587; lane 5 shows cells transfected with ZFN pair
15556/15590; lane 6 shows cells transfected with ZFN pair
15557/15587; lane 7 shows cells transfected with ZFN pair
15557/15590; and lane 8 shows cells transfected with ZFN pair
9931/10099. ZFN pairs are shown in Table 1.
[0044] FIGS. 7A and 7B depict ZFN-mediated insertion of a
promoterless GFP ORF. FIG. 7A is a schematic depicting integration
and mRNA expression of the GFP ORF into the region cleaved by the
ZFNs. FIG. 7B depicts insertion of the GFP ORF in the absence (lane
1) or presence of ZFNs (lane 2). The percentage of cells (9.6%)
with integrated GFP ORF in the presence of ZFNs (lane 2) is
indicated beneath lane 2.
[0045] FIGS. 8A through 8E depict integration of a donor containing
a promoter transcription unit (PTU). FIG. 8A shows the epigenetic
stability of GFP expression in K562 cells when driven by the
endogenous p84 promoter. The mean fluorescence intensity (MFI) of a
GFP-positive cell pool (crosses), a clone derived by limiting
dilution that is homozygous at p84 for the GFP ORF (squares) and
heterozygous for it (triangles), measured over 25 days--ca. 30 cell
doublings--of growth in nonselective medium is shown. Untransformed
K562 are also shown (diamonds). FIG. 8B depicts a graphical
schematic of tandem "marker-PTU" addition process showing the
integration of a shRNA expression cassette in addition to the GFP
ORF screening marker. FIG. 8C depicts efficient long-term function
of a PTU transferred to the p84 locus using ZFNs. Cells were (in
order of appearance in the figure) left untreated, transiently
transfected with an shRNA-encoding plasmid against CD58, or
transfected with ZFNs and a donor plasmid schematically depicted in
FIG. 8C. CD58 expression on the cell surface was assayed by
immunofluorescence and FACS using an anti-CD58 antibody. FIG. 8D
depicts the FACS staining profile of cells double-transgenic at
p84. FIG. 8E depicts the results of quantitative PCR-based assay on
GFP-positive cells carrying solely the GFP ORF (middle lane) or the
GFP ORF in tandem with a PTU encoding an shRNA against CD58 (right
lane). Numbers represent the percent of the population that has
been modified.
[0046] FIGS. 9A and 9B depict nucleus-wide molecular cytological
survey of ZFN action. FIG. 9A is a reproduction of a gel showing
comparison of genome editing efficiency driven by
IL2R.gamma.-targeting and p84-targeting ZFNs at their intended
loci. K562 cells were transfected with the indicated reagents. Gene
disruption frequency at the target loci was assayed by Surveyor.TM.
endonuclease as described in Miller et al. (2007) Nat. Biotechnol.
25(7):778-785 and is indicated below the appropriate lanes. FIG. 9B
is a graph depicting overall nucleus-wide levels of H2A.X staining
in cells treated as indicated, using a FACS based assay as
described in Miller et al. (2007) Nat. Biotechnol.
25(7):778-785.
DETAILED DESCRIPTION
[0047] The present disclosure relates to methods and composition
for targeted integration (TI) into the human PPP1R12C gene, which
lies on chromosome 19. PPP1R12C is the major site of integration
into the human genome of adeno-associated virus and no
pathophysiological event has ever been associated with AAV
infection (Warrington & Herzog (2006) Hum Genet 119:571-603),
indicating that the loss of PPP1R12C function is tolerated by human
cells and that this locus can be considered a "safe harbor" for
targeted integration. Moreover, the PPP1R12C gene is broadly
transcribed. Thus, the inserted (donor) sequence can be
promoterless and transcription of the integrated open reading frame
can occur from the endogenous gene promoter, which lowers the
likelihood of a severe adverse event due to random integration of
the donor and/or the spurious activation of an endogenous gene by
the promoter carried on the donor (see, e.g., Kohn et al. Nat Rev
Cancer 3:477-488)
[0048] Compositions useful for targeted cleavage and recombination
into the PPP1R12C gene include fusion proteins comprising a
cleavage domain (or a cleavage half-domain) and a zinc finger
binding domain, polynucleotides encoding these proteins and
combinations of polypeptides and polypeptide-encoding
polynucleotides. A zinc finger binding domain can comprise one or
more zinc fingers (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or more zinc
fingers), and can be engineered to bind to any sequence within
PPP1R12C. The presence of such a fusion protein (or proteins) in a
cell will result in binding of the fusion protein(s) to its (their)
binding site(s) and cleavage within the endogenous PPP1R12C
gene.
[0049] General
[0050] Practice of the methods, as well as preparation and use of
the compositions disclosed herein employ, unless otherwise
indicated, conventional techniques in molecular biology,
biochemistry, chromatin structure and analysis, computational
chemistry, cell culture, recombinant DNA and related fields as are
within the skill of the art. These techniques are fully explained
in the literature. See, for example, Sambrook et al., MOLECULAR
CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor
Laboratory Press, 1989 and Third edition, 2001; Ausubel et al.,
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New
York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY,
Academic Press, San Diego; Wolfe, CHROMATIN STRUCTURE AND FUNCTION,
Third edition, Academic Press, San Diego, 1998; METHODS IN
ENZYMOLOGY, Vol. 304, "Chromatin" (P. M. Wassarman and A. P.
Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN
MOLECULAR BIOLOGY, Vol. 119, "Chromatin Protocols" (P. B. Becker,
ed.) Humana Press, Totowa, 1999.
Definitions
[0051] The terms "nucleic acid," "polynucleotide," and
"oligonucleotide" are used interchangeably and refer to a
deoxyribonucleotide or ribonucleotide polymer, in linear or
circular conformation, and in either single- or double-stranded
form. For the purposes of the present disclosure, these terms are
not to be construed as limiting with respect to the length of a
polymer. The terms can encompass known analogues of natural
nucleotides, as well as nucleotides that are modified in the base,
sugar and/or phosphate moieties (e.g., phosphorothioate backbones).
In general, an analogue of a particular nucleotide has the same
base-pairing specificity; i.e., an analogue of A will base-pair
with T.
[0052] The terms "polypeptide," "peptide" and "protein" are used
interchangeably to refer to a polymer of amino acid residues. The
term also applies to amino acid polymers in which one or more amino
acids are chemical analogues or modified derivatives of a
corresponding naturally-occurring amino acids.
[0053] "Binding" refers to a sequence-specific, non-covalent
interaction between macromolecules (e.g., between a protein and a
nucleic acid). Not all components of a binding interaction need be
sequence-specific (e.g., contacts with phosphate residues in a DNA
backbone), as long as the interaction as a whole is
sequence-specific. Such interactions are generally characterized by
a dissociation constant (K.sub.d) of 10.sup.-6 M.sup.-1 or lower.
"Affinity" refers to the strength of binding: increased binding
affinity being correlated with a lower K.sub.d.
[0054] A "binding protein" is a protein that is able to bind
non-covalently to another molecule. A binding protein can bind to,
for example, a DNA molecule (a DNA-binding protein), an RNA
molecule (an RNA-binding protein) and/or a protein molecule (a
protein-binding protein). In the case of a protein-binding protein,
it can bind to itself (to form homodimers, homotrimers, etc.)
and/or it can bind to one or more molecules of a different protein
or proteins. A binding protein can have more than one type of
binding activity. For example, zinc finger proteins have
DNA-binding, RNA-binding and protein-binding activity.
[0055] A "zinc finger DNA binding protein" (or binding domain) is a
protein, or a domain within a larger protein, that binds DNA in a
sequence-specific manner through one or more zinc fingers, which
are regions of amino acid sequence within the binding domain whose
structure is stabilized through coordination of a zinc ion. The
term zinc finger DNA binding protein is often abbreviated as zinc
finger protein or ZFP.
[0056] Zinc finger binding domains can be "engineered" to bind to a
predetermined nucleotide sequence. Non-limiting examples of methods
for engineering zinc finger proteins are design and selection. A
designed zinc finger protein is a protein not occurring in nature
whose design/composition results principally from rational
criteria. Rational criteria for design include application of
substitution rules and computerized algorithms for processing
information in a database storing information of existing ZFP
designs and binding data. See, for example, U.S. Pat. Nos.
6,140,081; 6,453,242; and 6,534,261; see also International Patent
Publication Nos. WO 98/53058; WO 98/53059; WO 98/53060; WO
02/016536; and WO 03/016496.
[0057] A "selected" zinc finger protein is a protein not found in
nature whose production results primarily from an empirical process
such as phage display, interaction trap or hybrid selection. See
e.g., U.S. Pat. Nos. 5,789,538; 5,925,523; 6,007,988; 6,013,453;
and 6,200,759 and International Patent Publication Nos. WO
95/19431; WO 96/06166; WO 98/53057; WO 98/54311; WO 00/27878; WO
01/60970; WO 01/88197; and WO 02/099084.
[0058] The term "sequence" refers to a nucleotide sequence of any
length, which can be DNA or RNA; can be linear, circular or
branched and can be either single-stranded or double stranded. The
term "donor sequence" refers to a nucleotide sequence that is
inserted into a genome. A donor sequence can be of any length, for
example between 2 and 10,000 nucleotides in length (or any integer
value therebetween or thereabove), preferably between about 100 and
1,000 nucleotides in length (or any integer therebetween), more
preferably between about 200 and 500 nucleotides in length.
[0059] A "homologous, non-identical sequence" refers to a first
sequence which shares a degree of sequence identity with a second
sequence, but whose sequence is not identical to that of the second
sequence. For example, a polynucleotide comprising the wild-type
sequence of a mutant gene is homologous and non-identical to the
sequence of the mutant gene. In certain embodiments, the degree of
homology between the two sequences is sufficient to allow
homologous recombination therebetween, utilizing normal cellular
mechanisms. Two homologous non-identical sequences can be any
length and their degree of non-homology can be as small as a single
nucleotide (e.g., for correction of a genomic point mutation by
targeted homologous recombination) or as large as 10 or more
kilobases (e.g., for insertion of a gene at a predetermined ectopic
site in a chromosome). Two polynucleotides comprising the
homologous non-identical sequences need not be the same length. For
example, an exogenous polynucleotide (i.e., donor polynucleotide)
of between 20 and 10,000 nucleotides or nucleotide pairs can be
used.
[0060] Techniques for determining nucleic acid and amino acid
sequence identity are known in the art. Typically, such techniques
include determining the nucleotide sequence of the mRNA for a gene
and/or determining the amino acid sequence encoded thereby, and
comparing these sequences to a second nucleotide or amino acid
sequence. Genomic sequences can also be determined and compared in
this fashion. In general, identity refers to an exact
nucleotide-to-nucleotide or amino acid-to-amino acid correspondence
of two polynucleotides or polypeptide sequences, respectively. Two
or more sequences (polynucleotide or amino acid) can be compared by
determining their percent identity. The percent identity of two
sequences, whether nucleic acid or amino acid sequences, is the
number of exact matches between two aligned sequences divided by
the length of the shorter sequences and multiplied by 100. An
approximate alignment for nucleic acid sequences is provided by the
local homology algorithm of Smith and Waterman, Advances in Applied
Mathematics 2:482-489 (1981). This algorithm can be applied to
amino acid sequences by using the scoring matrix developed by
Dayhoff, Atlas of Protein Sequences and Structure, M. O. Dayhoff
ed., 5 suppl. 3:353-358, National Biomedical Research Foundation,
Washington, D.C., USA, and normalized by Gribskov, Nucl. Acids Res.
14(6):6745-6763 (1986). An exemplary implementation of this
algorithm to determine percent identity of a sequence is provided
by the Genetics Computer Group (Madison, Wis.) in the "BestFit"
utility application. The default parameters for this method are
described in the Wisconsin Sequence Analysis Package Program
Manual, Version 8 (1995) (available from Genetics Computer Group,
Madison, Wis.). A preferred method of establishing percent identity
in the context of the present disclosure is to use the MPSRCH
package of programs copyrighted by the University of Edinburgh,
developed by John F. Collins and Shane S. Sturrok, and distributed
by IntelliGenetics, Inc. (Mountain View, Calif.). From this suite
of packages the Smith-Waterman algorithm can be employed where
default parameters are used for the scoring table (for example, gap
open penalty of 12, gap extension penalty of one, and a gap of
six). From the data generated the "Match" value reflects sequence
identity. Other suitable programs for calculating the percent
identity or similarity between sequences are generally known in the
art, for example, another alignment program is BLAST, used with
default parameters. For example, BLASTN and BLASTP can be used
using the following default parameters: genetic code=standard;
filter=none; strand=both; cutoff=60; expect=10; Matrix=BLOSUM62;
Descriptions=50 sequences; sort by=HIGH SCORE;
Databases=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS
translations+Swiss protein+Spupdate+PIR. Details of these programs
can be found on the internet. With respect to sequences described
herein, the range of desired degrees of sequence identity is
approximately 80% to 100% and any integer value therebetween.
Typically the percent identities between sequences are at least
70-75%, preferably 80-82%, more preferably 85-90%, even more
preferably 92%, still more preferably 95%, and most preferably 98%
sequence identity.
[0061] Alternatively, the degree of sequence similarity between
polynucleotides can be determined by hybridization of
polynucleotides under conditions that allow formation of stable
duplexes between homologous regions, followed by digestion with
single-stranded-specific nuclease(s), and size determination of the
digested fragments. Two nucleic acid, or two polypeptide sequences
are substantially homologous to each other when the sequences
exhibit at least about 70%-75%, preferably 80%-82%, more preferably
85%-90%, even more preferably 92%, still more preferably 95%, and
most preferably 98% sequence identity over a defined length of the
molecules, as determined using the methods above. As used herein,
substantially homologous also refers to sequences showing complete
identity to a specified DNA or polypeptide sequence. DNA sequences
that are substantially homologous can be identified in a Southern
hybridization experiment under, for example, stringent conditions,
as defined for that particular system. Defining appropriate
hybridization conditions is within the skill of the art. See, e.g.,
Sambrook et al., supra; Nucleic Acid Hybridization: A Practical
Approach, editors B. D. Hames and S. J. Higgins, (1985) Oxford;
Washington, D.C.; IRL Press).
[0062] Selective hybridization of two nucleic acid fragments can be
determined as follows. The degree of sequence identity between two
nucleic acid molecules affects the efficiency and strength of
hybridization events between such molecules. A partially identical
nucleic acid sequence will at least partially inhibit the
hybridization of a completely identical sequence to a target
molecule. Inhibition of hybridization of the completely identical
sequence can be assessed using hybridization assays that are well
known in the art (e.g., Southern (DNA) blot, Northern (RNA) blot,
solution hybridization, or the like, see Sambrook et al., Molecular
Cloning: A Laboratory Manual, Second Edition, (1989) Cold Spring
Harbor, N.Y.). Such assays can be conducted using varying degrees
of selectivity, for example, using conditions varying from low to
high stringency. If conditions of low stringency are employed, the
absence of non-specific binding can be assessed using a secondary
probe that lacks even a partial degree of sequence identity (for
example, a probe having less than about 30% sequence identity with
the target molecule), such that, in the absence of non-specific
binding events, the secondary probe will not hybridize to the
target.
[0063] When utilizing a hybridization-based detection system, a
nucleic acid probe is chosen that is complementary to a reference
nucleic acid sequence, and then by selection of appropriate
conditions the probe and the reference sequence selectively
hybridize, or bind, to each other to form a duplex molecule. A
nucleic acid molecule that is capable of hybridizing selectively to
a reference sequence under moderately stringent hybridization
conditions typically hybridizes under conditions that allow
detection of a target nucleic acid sequence of at least about 10-14
nucleotides in length having at least approximately 70% sequence
identity with the sequence of the selected nucleic acid probe.
Stringent hybridization conditions typically allow detection of
target nucleic acid sequences of at least about 10-14 nucleotides
in length having a sequence identity of greater than about 90-95%
with the sequence of the selected nucleic acid probe. Hybridization
conditions useful for probe/reference sequence hybridization, where
the probe and reference sequence have a specific degree of sequence
identity, can be determined as is known in the art (see, for
example, Nucleic Acid Hybridization: A Practical Approach, editors
B. D. Hames and S. J. Higgins, (1985) Oxford; Washington, D.C.; IRL
Press).
[0064] Conditions for hybridization are well-known to those of
skill in the art. Hybridization stringency refers to the degree to
which hybridization conditions disfavor the formation of hybrids
containing mismatched nucleotides, with higher stringency
correlated with a lower tolerance for mismatched hybrids. Factors
that affect the stringency of hybridization are well-known to those
of skill in the art and include, but are not limited to,
temperature, pH, ionic strength, and concentration of organic
solvents such as, for example, formamide and dimethylsulfoxide. As
is known to those of skill in the art, hybridization stringency is
increased by higher temperatures, lower ionic strength and lower
solvent concentrations.
[0065] With respect to stringency conditions for hybridization, it
is well known in the art that numerous equivalent conditions can be
employed to establish a particular stringency by varying, for
example, the following factors: the length and nature of the
sequences, base composition of the various sequences,
concentrations of salts and other hybridization solution
components, the presence or absence of blocking agents in the
hybridization solutions (e.g., dextran sulfate, and polyethylene
glycol), hybridization reaction temperature and time parameters, as
well as, varying wash conditions. The selection of a particular set
of hybridization conditions is selected following standard methods
in the art (see, for example, Sambrook, et al., Molecular Cloning:
A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor,
N.Y.).
[0066] "Recombination" refers to a process of exchange of genetic
information between two polynucleotides. For the purposes of this
disclosure, "homologous recombination (HR)" refers to the
specialized form of such exchange that takes place, for example,
during repair of double-strand breaks in cells. This process
requires nucleotide sequence homology, uses a "donor" molecule to
template repair of a "target" molecule (i.e., the one that
experienced the double-strand break), and is variously known as
"non-crossover gene conversion" or "short tract gene conversion,"
because it leads to the transfer of genetic information from the
donor to the target. Without wishing to be bound by any particular
theory, such transfer can involve mismatch correction of
heteroduplex DNA that forms between the broken target and the
donor, and/or "synthesis-dependent strand annealing," in which the
donor is used to resynthesize genetic information that will become
part of the target, and/or related processes. Such specialized HR
often results in an alteration of the sequence of the target
molecule such that part or all of the sequence of the donor
polynucleotide is incorporated into the target polynucleotide.
[0067] "Cleavage" refers to the breakage of the covalent backbone
of a DNA molecule. Cleavage can be initiated by a variety of
methods including, but not limited to, enzymatic or chemical
hydrolysis of a phosphodiester bond. Both single-stranded cleavage
and double-stranded cleavage are possible, and double-stranded
cleavage can occur as a result of two distinct single-stranded
cleavage events. DNA cleavage can result in the production of
either blunt ends or staggered ends. In certain embodiments, fusion
polypeptides are used for targeted double-stranded DNA
cleavage.
[0068] A "cleavage domain" comprises one or more polypeptide
sequences which possesses catalytic activity for DNA cleavage. A
cleavage domain can be contained in a single polypeptide chain or
cleavage activity can result from the association of two (or more)
polypeptides.
[0069] A "cleavage half-domain" is a polypeptide sequence which, in
conjunction with a second polypeptide (either identical or
different) forms a complex having cleavage activity (preferably
double-strand cleavage activity).
[0070] "Chromatin" is the nucleoprotein structure comprising the
cellular genome. Cellular chromatin comprises nucleic acid,
primarily DNA, and protein, including histones and non-histone
chromosomal proteins. The majority of eukaryotic cellular chromatin
exists in the form of nucleosomes, wherein a nucleosome core
comprises approximately 150 base pairs of DNA associated with an
octamer comprising two each of histones H2A, H2B, H3 and H4; and
linker DNA (of variable length depending on the organism) extends
between nucleosome cores. A molecule of histone H1 is generally
associated with the linker DNA. For the purposes of the present
disclosure, the term "chromatin" is meant to encompass all types of
cellular nucleoprotein, both prokaryotic and eukaryotic. Cellular
chromatin includes both chromosomal and episomal chromatin.
[0071] A "chromosome," is a chromatin complex comprising all or a
portion of the genome of a cell. The genome of a cell is often
characterized by its karyotype, which is the collection of all the
chromosomes that comprise the genome of the cell. The genome of a
cell can comprise one or more chromosomes.
[0072] An "episome" is a replicating nucleic acid, nucleoprotein
complex or other structure comprising a nucleic acid that is not
part of the chromosomal karyotype of a cell. Examples of episomes
include plasmids and certain viral genomes.
[0073] An "accessible region" is a site in cellular chromatin in
which a target site present in the nucleic acid can be bound by an
exogenous molecule which recognizes the target site. Without
wishing to be bound by any particular theory, it is believed that
an accessible region is one that is not packaged into a nucleosomal
structure. The distinct structure of an accessible region can often
be detected by its sensitivity to chemical and enzymatic probes,
for example, nucleases.
[0074] A "target site" or "target sequence" is a nucleic acid
sequence that defines a portion of a nucleic acid to which a
binding molecule will bind, provided sufficient conditions for
binding exist. For example, the sequence 5'-GAATTC-3' is a target
site for the Eco RI restriction endonuclease.
[0075] An "exogenous" molecule is a molecule that is not normally
present in a cell, but can be introduced into a cell by one or more
genetic, biochemical or other methods. "Normal presence in the
cell" is determined with respect to the particular developmental
stage and environmental conditions of the cell. Thus, for example,
a molecule that is present only during embryonic development of
muscle is an exogenous molecule with respect to an adult muscle
cell. Similarly, a molecule induced by heat shock is an exogenous
molecule with respect to a non-heat-shocked cell. An exogenous
molecule can comprise, for example, a coding sequence for any
polypeptide or fragment thereof, a functioning version of a
malfunctioning endogenous molecule or a malfunctioning version of a
normally-functioning endogenous molecule. Additionally, an
exogenous molecule can comprise a coding sequence from another
species that is an ortholog of an endogenous gene in the host
cell.
[0076] An exogenous molecule can be, among other things, a small
molecule, such as is generated by a combinatorial chemistry
process, or a macromolecule such as a protein, nucleic acid,
carbohydrate, lipid, glycoprotein, lipoprotein, polysaccharide, any
modified derivative of the above molecules, or any complex
comprising one or more of the above molecules. Nucleic acids
include DNA and RNA, can be single- or double-stranded; can be
linear, branched or circular; and can be of any length. Nucleic
acids include those capable of forming duplexes, as well as
triplex-forming nucleic acids. See, for example, U.S. Pat. Nos.
5,176,996 and 5,422,251. Proteins include, but are not limited to,
DNA-binding proteins, transcription factors, chromatin remodeling
factors, methylated DNA binding proteins, polymerases, methylases,
demethylases, acetylases, deacetylases, kinases, phosphatases,
integrases, recombinases, ligases, topoisomerases, gyrases and
helicases.
[0077] An exogenous molecule can be the same type of molecule as an
endogenous molecule, e.g., an exogenous protein or nucleic acid.
For example, an exogenous nucleic acid can comprise an infecting
viral genome, a plasmid or episome introduced into a cell, or a
chromosome that is not normally present in the cell. Methods for
the introduction of exogenous molecules into cells are known to
those of skill in the art and include, but are not limited to,
lipid-mediated transfer (i.e., liposomes, including neutral and
cationic lipids), electroporation, direct injection, cell fusion,
particle bombardment, calcium phosphate co-precipitation,
DEAE-dextran-mediated transfer and viral vector-mediated
transfer.
[0078] By contrast, an "endogenous" molecule is one that is
normally present in a particular cell at a particular developmental
stage under particular environmental conditions. For example, an
endogenous nucleic acid can comprise a chromosome, the genome of a
mitochondrion, chloroplast or other organelle, or a
naturally-occurring episomal nucleic acid. Additional endogenous
molecules can include proteins, for example, transcription factors
and enzymes.
[0079] As used herein, the term "product of an exogenous nucleic
acid" includes both polynucleotide and polypeptide products, for
example, transcription products (polynucleotides such as RNA) and
translation products (polypeptides).
[0080] A "fusion" molecule is a molecule in which two or more
subunit molecules are linked, preferably covalently. The subunit
molecules can be the same chemical type of molecule, or can be
different chemical types of molecules. Examples of the first type
of fusion molecule include, but are not limited to, fusion proteins
(for example, a fusion between a ZFP DNA-binding domain and a
cleavage domain) and fusion nucleic acids (for example, a nucleic
acid encoding the fusion protein described supra). Examples of the
second type of fusion molecule include, but are not limited to, a
fusion between a triplex-forming nucleic acid and a polypeptide,
and a fusion between a minor groove binder and a nucleic acid.
[0081] Expression of a fusion protein in a cell can result from
delivery of the fusion protein to the cell or by delivery of a
polynucleotide encoding the fusion protein to a cell, wherein the
polynucleotide is transcribed, and the transcript is translated, to
generate the fusion protein. Trans-splicing, polypeptide cleavage
and polypeptide ligation can also be involved in expression of a
protein in a cell. Methods for polynucleotide and polypeptide
delivery to cells are presented elsewhere in this disclosure.
[0082] A "gene," for the purposes of the present disclosure,
includes a DNA region encoding a gene product (see infra), as well
as all DNA regions which regulate the production of the gene
product, whether or not such regulatory sequences are adjacent to
coding and/or transcribed sequences. Accordingly, a gene includes,
but is not necessarily limited to, promoter sequences, terminators,
translational regulatory sequences such as ribosome binding sites
and internal ribosome entry sites, enhancers, silencers,
insulators, boundary elements, replication origins, matrix
attachment sites and locus control regions.
[0083] "Gene expression" refers to the conversion of the
information, contained in a gene, into a gene product. A gene
product can be the direct transcriptional product of a gene (e.g.,
mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any
other type of RNA) or a protein produced by translation of a mRNA.
Gene products also include RNAs which are modified, by processes
such as capping, polyadenylation, methylation, and editing, and
proteins modified by, for example, methylation, acetylation,
phosphorylation, ubiquitination, ADP-ribosylation, myristilation,
and glycosylation.
[0084] "Modulation" of gene expression refers to a change in the
activity of a gene. Modulation of expression can include, but is
not limited to, gene activation and gene repression.
[0085] "Eukaryotic" cells include, but are not limited to, fungal
cells (such as yeast), plant cells, animal cells, mammalian cells
and human cells.
[0086] A "region of interest" is any region of cellular chromatin,
such as, for example, a gene or a non-coding sequence within or
adjacent to a gene, in which it is desirable to bind an exogenous
molecule. Binding can be for the purposes of targeted DNA cleavage
and/or targeted recombination. A region of interest can be present
in a chromosome, an episome, an organellar genome (e.g.,
mitochondrial, chloroplast), or an infecting viral genome, for
example. A region of interest can be within the coding region of a
gene, within transcribed non-coding regions such as, for example,
leader sequences, trailer sequences or introns, or within
non-transcribed regions, either upstream or downstream of the
coding region. A region of interest can be as small as a single
nucleotide pair or up to 2,000 nucleotide pairs in length, or any
integral value of nucleotide pairs.
[0087] The terms "operative linkage" and "operatively linked" (or
"operably linked") are used interchangeably with reference to a
juxtaposition of two or more components (such as sequence
elements), in which the components are arranged such that both
components function normally and allow the possibility that at
least one of the components can mediate a function that is exerted
upon at least one of the other components. By way of illustration,
a transcriptional regulatory sequence, such as a promoter, is
operatively linked to a coding sequence if the transcriptional
regulatory sequence controls the level of transcription of the
coding sequence in response to the presence or absence of one or
more transcriptional regulatory factors. A transcriptional
regulatory sequence is generally operatively linked in cis with a
coding sequence, but need not be directly adjacent to it. For
example, an enhancer is a transcriptional regulatory sequence that
is operatively linked to a coding sequence, even though they are
not contiguous.
[0088] With respect to fusion polypeptides, the term "operatively
linked" can refer to the fact that each of the components performs
the same function in linkage to the other component as it would if
it were not so linked. For example, with respect to a fusion
polypeptide in which a ZFP DNA-binding domain is fused to a
cleavage domain, the ZFP DNA-binding domain and the cleavage domain
are in operative linkage if, in the fusion polypeptide, the ZFP
DNA-binding domain portion is able to bind its target site and/or
its binding site, while the cleavage domain is able to cleave DNA
in the vicinity of the target site.
[0089] A "functional fragment" of a protein, polypeptide or nucleic
acid is a protein, polypeptide or nucleic acid whose sequence is
not identical to the full-length protein, polypeptide or nucleic
acid, yet retains the same function as the full-length protein,
polypeptide or nucleic acid. A functional fragment can possess
more, fewer, or the same number of residues as the corresponding
native molecule, and/or can contain one ore more amino acid or
nucleotide substitutions. Methods for determining the function of a
nucleic acid (e.g., coding function, ability to hybridize to
another nucleic acid) are well-known in the art. Similarly, methods
for determining protein function are well-known. For example, the
DNA-binding function of a polypeptide can be determined, for
example, by filter-binding, electrophoretic mobility-shift, or
immunoprecipitation assays. DNA cleavage can be assayed by gel
electrophoresis. See Ausubel et al., supra. The ability of a
protein to interact with another protein can be determined, for
example, by co-immunoprecipitation, two-hybrid assays or
complementation, both genetic and biochemical. See, for example,
Fields et al. (1989) Nature 340:245-246; U.S. Pat. No. 5,585,245
and International Patent Publication No. WO 98/44350.
[0090] Target Sites
[0091] The disclosed methods and compositions include fusion
proteins comprising a cleavage domain (or a cleavage half-domain)
and a zinc finger domain, in which the zinc finger domain, by
binding to a sequence in the human PPP1R12C locus directs the
activity of the cleavage domain (or cleavage half-domain) to the
vicinity of the sequence and, hence, induces cleavage (e.g., a
double stranded break) in PPP1R12C. As set forth elsewhere in this
disclosure, a zinc finger domain can be engineered to bind to
virtually any desired sequence. Accordingly, one or more zinc
finger binding domains can be engineered to bind to one or more
sequences in the PPP1R12C gene. Expression of a fusion protein
comprising a zinc finger binding domain and a cleavage domain (or
of two fusion proteins, each comprising a zinc finger binding
domain and a cleavage half-domain), in a cell, effects cleavage in
the PPP1R12C gene.
[0092] Selection of a sequence in PPP1R12C for binding by a zinc
finger domain (e.g., a target site) can be accomplished, for
example, according to the methods disclosed in co-owned U.S. Pat.
No. 6,453,242 (issued Sep. 17, 2002), which also discloses methods
for designing ZFPs to bind to a selected sequence. It will be clear
to those skilled in the art that simple visual inspection of a
nucleotide sequence can also be used for selection of a target
site. Accordingly, any means for target site selection can be used
in the methods described herein.
[0093] Target sites are generally composed of a plurality of
adjacent target subsites. A target subsite refers to the sequence
(usually either a nucleotide triplet, or a nucleotide quadruplet
that can overlap by one nucleotide with an adjacent quadruplet)
bound by an individual zinc finger. See, for example, International
Patent Publication No. WO 02/077227. If the strand with which a
zinc finger protein makes most contacts is designated the target
strand "primary recognition strand," or "primary contact strand,"
some zinc finger proteins bind to a three base triplet in the
target strand and a fourth base on the non-target strand. A target
site generally has a length of at least 9 nucleotides and,
accordingly, is bound by a zinc finger binding domain comprising at
least three zinc fingers. However binding of, for example, a
4-finger binding domain to a 12-nucleotide target site, a 5-finger
binding domain to a 15-nucleotide target site or a 6-finger binding
domain to an 18-nucleotide target site, is also possible. As will
be apparent, binding of larger binding domains (e.g., 7-, 8-,
9-finger and more) to longer target sites is also possible.
[0094] It is not necessary for a target site to be a multiple of
three nucleotides. For example, in cases in which cross-strand
interactions occur (see, e.g., U.S. Pat. No. 6,453,242 and
International Patent Publication No. WO 02/077227), one or more of
the individual zinc fingers of a multi-finger binding domain can
bind to overlapping quadruplet subsites. As a result, a
three-finger protein can bind a 10-nucleotide sequence, wherein the
tenth nucleotide is part of a quadruplet bound by a terminal
finger, a four-finger protein can bind a 13-nucleotide sequence,
wherein the thirteenth nucleotide is part of a quadruplet bound by
a terminal finger, etc.
[0095] The length and nature of amino acid linker sequences between
individual zinc fingers in a multi-finger binding domain also
affects binding to a target sequence. For example, the presence of
a so-called "non-canonical linker," "long linker" or "structured
linker" between adjacent zinc fingers in a multi-finger binding
domain can allow those fingers to bind subsites which are not
immediately adjacent. Non-limiting examples of such linkers are
described, for example, in U.S. Pat. No. 6,479,626 and
International Patent Publication No. WO 01/53480. Accordingly, one
or more subsites, in a target site for a zinc finger binding
domain, can be separated from each other by 1, 2, 3, 4, 5 or more
nucleotides. To provide but one example, a four-finger binding
domain can bind to a 13-nucleotide target site comprising, in
sequence, two contiguous 3-nucleotide subsites, an intervening
nucleotide, and two contiguous triplet subsites.
[0096] Distance between sequences (e.g., target sites) refers to
the number of nucleotides or nucleotide pairs intervening between
two sequences, as measured from the edges of the sequences nearest
each other.
[0097] In certain embodiments in which cleavage depends on the
binding of two zinc finger domain/cleavage half-domain fusion
molecules to separate target sites, the two target sites can be on
opposite DNA strands (Example 1). In other embodiments, both target
sites are on the same DNA strand.
[0098] DNA-Binding Domains
[0099] Any DNA-binding domain can be used in the methods disclosed
herein. In certain embodiments, the DNA binding domain comprises a
zinc finger protein. A zinc finger binding domain comprises one or
more zinc fingers. Miller et al. (1985) EMBO J. 4:1609-1614; Rhodes
(1993) Scientific American February: 56-65; U.S. Pat. No.
6,453,242. The zinc finger binding domains described herein
generally include 2, 3, 4, 5, 6 or even more zinc fingers.
[0100] Typically, a single zinc finger domain is about 30 amino
acids in length. Structural studies have demonstrated that each
zinc finger domain (motif) contains two beta sheets (held in a beta
turn which contains the two invariant cysteine residues) and an
alpha helix (containing the two invariant histidine residues),
which are held in a particular conformation through coordination of
a zinc atom by the two cysteines and the two histidines.
[0101] Zinc fingers include both canonical C.sub.2H.sub.2 zinc
fingers (i.e., those in which the zinc ion is coordinated by two
cysteine and two histidine residues) and non-canonical zinc fingers
such as, for example, C.sub.3H zinc fingers (those in which the
zinc ion is coordinated by three cysteine residues and one
histidine residue) and C.sub.4 zinc fingers (those in which the
zinc ion is coordinated by four cysteine residues). See also
International Patent Publication No. WO 02/057293.
[0102] Zinc finger binding domains can be engineered to bind to a
target site (see above) in PPP1R12C using standard techniques. See,
Example 1; co-owned U.S. Pat. Nos. 6,453,242 and 6,534,261,
including references cited therein. An engineered zinc finger
binding domain can have a novel binding specificity, compared to a
naturally-occurring zinc finger protein. Engineering methods
include, but are not limited to, rational design and various types
of selection. Rational design includes, for example, using
databases comprising triplet (or quadruplet) nucleotide sequences
and individual zinc finger amino acid sequences, in which each
triplet or quadruplet nucleotide sequence is associated with one or
more amino acid sequences of zinc fingers which bind the particular
triplet or quadruplet sequence.
[0103] Exemplary selection methods, including phage display and
two-hybrid systems, are disclosed in U.S. Pat. Nos. 5,789,538;
5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759;
and 6,242,568; as well as International Patent Publication Nos. WO
98/37186; WO 98/53057; WO 00/27878; WO 01/88197 and GB
2,338,237.
[0104] Enhancement of binding specificity for zinc finger binding
domains has been described, for example, in co-owned International
Patent Publication No. WO 02/077227.
[0105] Since an individual zinc finger binds to a three-nucleotide
(i.e., triplet) sequence (or a four-nucleotide sequence which can
overlap, by one nucleotide, with the four-nucleotide binding site
of an adjacent zinc finger), the length of a sequence to which a
zinc finger binding domain is engineered to bind (e.g., a target
sequence) will determine the number of zinc fingers in an
engineered zinc finger binding domain. For example, for ZFPs in
which the finger motifs do not bind to overlapping subsites, a
six-nucleotide target sequence is bound by a two-finger binding
domain; a nine-nucleotide target sequence is bound by a
three-finger binding domain, etc. As noted herein, binding sites
for individual zinc fingers (i.e., subsites) in a target site need
not be contiguous, but can be separated by one or several
nucleotides, depending on the length and nature of the amino acids
sequences between the zinc fingers (i.e., the inter-finger linkers)
in a multi-finger binding domain.
[0106] In a multi-finger zinc finger binding domain, adjacent zinc
fingers can be separated by amino acid linker sequences of
approximately 5 amino acids (so-called "canonical" inter-finger
linkers) or, alternatively, by one or more non-canonical linkers.
See, e.g., co-owned U.S. Pat. Nos. 6,453,242 and 6,534,261. For
engineered zinc finger binding domains comprising more than three
fingers, insertion of longer ("non-canonical") inter-finger linkers
between certain of the zinc fingers may be preferred as it may
increase the affinity and/or specificity of binding by the binding
domain. See, for example, U.S. Pat. No. 6,479,626 and International
Patent Publication No. WO 01/53480. Accordingly, multi-finger zinc
finger binding domains can also be characterized with respect to
the presence and location of non-canonical inter-finger linkers.
For example, a six-finger zinc finger binding domain comprising
three fingers (joined by two canonical inter-finger linkers), a
long linker and three additional fingers (joined by two canonical
inter-finger linkers) is denoted a 2.times.3 configuration.
Similarly, a binding domain comprising two fingers (with a
canonical linker therebetween), a long linker and two additional
fingers (joined by a canonical linker) is denoted a 2.times.2
protein. A protein comprising three two-finger units (in each of
which the two fingers are joined by a canonical linker), and in
which each two-finger unit is joined to the adjacent two finger
unit by a long linker, is referred to as a 3.times.2 protein.
[0107] The presence of a long or non-canonical inter-finger linker
between two adjacent zinc fingers in a multi-finger binding domain
often allows the two fingers to bind to subsites which are not
immediately contiguous in the target sequence. Accordingly, there
can be gaps of one or more nucleotides between subsites in a target
site; i.e., a target site can contain one or more nucleotides that
are not contacted by a zinc finger. For example, a 2.times.2 zinc
finger binding domain can bind to two six-nucleotide sequences
separated by one nucleotide, i.e., it binds to a 13-nucleotide
target site. See also Moore et al. (2001a) Proc. Natl. Acad. Sci.
USA 98:1432-1436; Moore et al. (2001b) Proc. Natl. Acad. Sci. USA
98:1437-1441 and International Patent Publication No. WO
01/53480.
[0108] As mentioned previously, a target subsite is a three- or
four-nucleotide sequence that is bound by a single zinc finger. For
certain purposes, a two-finger unit is denoted a binding module. A
binding module can be obtained by, for example, selecting for two
adjacent fingers in the context of a multi-finger protein
(generally three fingers) which bind a particular six-nucleotide
target sequence. Alternatively, modules can be constructed by
assembly of individual zinc fingers. See also International Patent
Publication Nos. WO 98/53057 and WO 01/53480.
[0109] Alternatively, the DNA-binding domain may be derived from a
nuclease. For example, the recognition sequences of homing
endonucleases and meganucleases such as I-SceI, I-CeuI, PI-PspI,
PI-Sce, I-SceIV, I-CsmI, I-PanI, I-SceII, I-PpoI, I-SceIII, I-CreI,
I-TevI, I-TevII and I-TevIII are known. See also U.S. Pat. No.
5,420,032; U.S. Pat. No. 6,833,252; Belfort et al. (1997) Nucleic
Acids Res. 25:3379-3388; Dujon et al. (1989) Gene 82:115-118;
Perler et al. (1994) Nucleic Acids Res. 22, 1125-1127; Jasin (1996)
Trends Genet. 12:224-228; Gimble et al. (1996)J. Mol. Biol.
263:163-180; Argast et al. (1998) J. Mol. Biol. 280:345-353 and the
New England Biolabs catalogue. In addition, the DNA-binding
specificity of homing endonucleases and meganucleases can be
engineered to bind non-natural target sites. See, for example,
Chevalier et al. (2002) Molec. Cell 10:895-905; Epinat et al.
(2003) Nucleic Acids Res. 31:2952-2962; Ashworth et al. (2006)
Nature 441:656-659; Paques et al. (2007) Current Gene Therapy
7:49-66; U.S. Patent Publication No. 2007/0117128.
[0110] Cleavage Domains
[0111] The cleavage domain portion of the fusion proteins disclosed
herein can be obtained from any endonuclease or exonuclease.
Exemplary endonucleases from which a cleavage domain can be derived
include, but are not limited to, restriction endonucleases and
homing endonucleases. See, for example, 2002-2003 Catalogue, New
England Biolabs, Beverly, Mass.; and Belfort et al. (1997) Nucleic
Acids Res. 25:3379-3388. Additional enzymes which cleave DNA are
known (e.g., 51 Nuclease; mung bean nuclease; pancreatic DNase I;
micrococcal nuclease; yeast HO endonuclease; see also Linn et al.
(eds.) Nucleases, Cold Spring Harbor Laboratory Press, 1993). Non
limiting examples of homing endonucleases and meganucleases include
I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-SceII,
I-PpoI, I-SceIII, I-CreI, I-TevI, I-TevII and I-TevIII are known.
See also U.S. Pat. No. 5,420,032; U.S. Pat. No. 6,833,252; Belfort
et al. (1997) Nucleic Acids Res. 25:3379-3388; Dujon et al. (1989)
Gene 82:115-118; Perler et al. (1994) Nucleic Acids Res. 22,
1125-1127; Jasin (1996) Trends Genet. 12:224-228; Gimble et al.
(1996)J. Mol. Biol. 263:163-180; Argast et al. (1998)J. Mol. Biol.
280:345-353 and the New England Biolabs catalogue. One or more of
these enzymes (or functional fragments thereof) can be used as a
source of cleavage domains and cleavage half-domains.
[0112] Restriction endonucleases (restriction enzymes) are present
in many species and are capable of sequence-specific binding to DNA
(at a recognition site), and cleaving DNA at or near the site of
binding. Certain restriction enzymes (e.g., Type IIS) cleave DNA at
sites removed from the recognition site and have separable binding
and cleavage domains. For example, the Type IIS enzyme Fok I
catalyzes double-stranded cleavage of DNA, at 9 nucleotides from
its recognition site on one strand and 13 nucleotides from its
recognition site on the other. See, for example, U.S. Pat. Nos.
5,356,802; 5,436,150; and 5,487,994; as well as Li et al. (1992)
Proc. Natl. Acad. Sci. USA 89:4275-4279; Li et al. (1993) Proc.
Natl. Acad. Sci. USA 90:2764-2768; Kim et al. (1994a) Proc. Natl.
Acad. Sci. USA 91:883-887; Kim et al. (1994b) J. Biol. Chem.
269:31,978-31,982. Thus, in one embodiment, fusion proteins
comprise the cleavage domain (or cleavage half-domain) from at
least one Type IIS restriction enzyme and one or more zinc finger
binding domains, which may or may not be engineered.
[0113] An exemplary Type IIS restriction enzyme, whose cleavage
domain is separable from the binding domain, is Fok I. This
particular enzyme is active as a dimer. Bitinaite et al. (1998)
Proc. Natl. Acad. Sci. USA 95: 10,570-10,575. Accordingly, for the
purposes of the present disclosure, the portion of the Fok I enzyme
used in the disclosed fusion proteins is considered a cleavage
half-domain. Thus, for targeted double-stranded cleavage and/or
targeted replacement of cellular sequences using zinc finger-Fok I
fusions, two fusion proteins, each comprising a FokI cleavage
half-domain, can be used to reconstitute a catalytically active
cleavage domain. Alternatively, a single polypeptide molecule
containing a zinc finger binding domain and two Fok I cleavage
half-domains can also be used. Parameters for targeted cleavage and
targeted sequence alteration using zinc finger-Fok I fusions are
provided elsewhere in this disclosure.
[0114] A cleavage domain or cleavage half-domain can be any portion
of a protein that retains cleavage activity, or that retains the
ability to multimerize (e.g., dimerize) to form a functional
cleavage domain.
[0115] Exemplary Type IIS restriction enzymes are described in
co-owned International Patent Publication No. WO 2007/014275,
incorporated by reference herein in its entirety.
[0116] To enhance cleavage specificity, cleavage domains may also
be modified. In certain embodiments, variants of the cleavage
half-domain are employed, which variants that minimize or prevent
homodimerization of the cleavage half-domains. Non-limiting
examples of such modified cleavage half-domains are described in
detail in International Patent Publication No. WO 2007/014275,
incorporated by reference in its entirety herein. See, also,
Examples. In certain embodiments, the cleavage domain comprises an
engineered cleavage half-domain (also referred to as dimerization
domain mutants) that minimize or prevent homodimerization are known
to those of skill the art and described for example in U.S. Patent
Publication Nos. 2005/0064474 and 2006/0188987, incorporated by
reference in their entireties herein. Amino acid residues at
positions 446, 447, 479, 483, 484, 486, 487, 490, 491, 496, 498,
499, 500, 531, 534, 537, and 538 of Fok I are all targets for
influencing dimerization of the Fok I cleavage half-domains. See,
e.g., U.S. Patent Publication Nos. 2005/0064474 and 2006/0188987;
International Patent Publication No. WO 07/139898; Miller et al.
(2007) Nat. Biotechnol. 25(7):778-785.
[0117] Additional engineered cleavage half-domains of Fok I form an
obligate heterodimers can also be used in the ZFNs described
herein. The first cleavage half-domain includes mutations at amino
acid residues at positions 490 and 538 of Fok I and the second
cleavage half-domain includes mutations at amino acid residues 486
and 499.
[0118] In certain embodiments, the cleavage domain comprises two
cleavage half-domains, both of which are part of a single
polypeptide comprising a binding domain, a first cleavage
half-domain and a second cleavage half-domain. The cleavage
half-domains can have the same amino acid sequence or different
amino acid sequences, so long as they function to cleave the
DNA.
[0119] In general, two fusion proteins are required for cleavage if
the fusion proteins comprise cleavage half-domains. Alternatively,
a single protein comprising two cleavage half-domains can be used.
The two cleavage half-domains can be derived from the same
endonuclease (or functional fragments thereof), or each cleavage
half-domain can be derived from a different endonuclease (or
functional fragments thereof). In addition, the target sites for
the two fusion proteins are preferably disposed, with respect to
each other, such that binding of the two fusion proteins to their
respective target sites places the cleavage half-domains in a
spatial orientation to each other that allows the cleavage
half-domains to form a functional cleavage domain, e.g., by
dimerizing. Thus, in certain embodiments, the near edges of the
target sites are separated by 5-8 nucleotides or by 15-18
nucleotides. However any integral number of nucleotides or
nucleotide pairs can intervene between two target sites (e.g., from
2 to 50 nucleotides or more). In general, the point of cleavage
lies between the target sites.
[0120] Zinc Finger Domain-Cleavage Domain Fusions
[0121] Methods for design and construction of fusion proteins (and
polynucleotides encoding same) are known to those of skill in the
art. For example, methods for the design and construction of fusion
protein comprising zinc finger proteins (and polynucleotides
encoding same) are described in co-owned U.S. Pat. Nos. 6,453,242
and 6,534,261; and International Patent Publication No. WO
2007/014275. In certain embodiments, polynucleotides encoding such
fusion proteins are constructed. These polynucleotides can be
inserted into a vector and the vector can be introduced into a cell
(see below for additional disclosure regarding vectors and methods
for introducing polynucleotides into cells).
[0122] In certain embodiments of the methods described herein, a
fusion protein comprises a zinc finger binding domain and a
cleavage half-domain from the Fok I restriction enzyme, and two
such fusion proteins are expressed in a cell. Expression of two
fusion proteins in a cell can result from delivery of the two
proteins to the cell; delivery of one protein and one nucleic acid
encoding one of the proteins to the cell; delivery of two nucleic
acids, each encoding one of the proteins, to the cell; or by
delivery of a single nucleic acid, encoding both proteins, to the
cell. In additional embodiments, a fusion protein comprises a
single polypeptide chain comprising two cleavage half domains and a
zinc finger binding domain. In this case, a single fusion protein
is expressed in a cell and, without wishing to be bound by theory,
is believed to cleave DNA as a result of formation of an
intramolecular dimer of the cleavage half-domains.
[0123] Two fusion proteins, each comprising a zinc finger binding
domain and a cleavage half-domain, may be expressed in a cell, and
bind to target sites which are juxtaposed in such a way that a
functional cleavage domain is reconstituted and DNA is cleaved in
the vicinity of the target sites. In one embodiment, cleavage
occurs between the target sites of the two zinc finger binding
domains. One or both of the zinc finger binding domains and/or
cleavage domains can be engineered. See, Example 1.
[0124] The components of the fusion proteins (e.g., ZFP-Fok I
fusions) may be arranged such that the zinc finger domain is
nearest the amino terminus of the fusion protein, and the cleavage
half-domain is nearest the carboxy-terminus. Dimerization of the
cleavage half-domains to form a functional nuclease is brought
about by binding of the fusion proteins to sites on opposite DNA
strands, with the 5' ends of the binding sites being proximal to
each other.
[0125] Alternatively, the components of the fusion proteins (e.g.,
ZFP-Fok I fusions) may be arranged such that the cleavage
half-domain is nearest the amino terminus of the fusion protein,
and the zinc finger domain is nearest the carboxy-terminus. In
these embodiments, dimerization of the cleavage half-domains to
form a functional nuclease is brought about by binding of the
fusion proteins to sites on opposite DNA strands, with the 3' ends
of the binding sites being proximal to each other.
[0126] In yet additional embodiments, a first fusion protein
contains the cleavage half-domain nearest the amino terminus of the
fusion protein, and the zinc finger domain nearest the
carboxy-terminus, and a second fusion protein is arranged such that
the zinc finger domain is nearest the amino terminus of the fusion
protein, and the cleavage half-domain is nearest the
carboxy-terminus. In these embodiments, both fusion proteins bind
to the same DNA strand, with the binding site of the first fusion
protein containing the zinc finger domain nearest the carboxy
terminus located to the 5' side of the binding site of the second
fusion protein containing the zinc finger domain nearest the amino
terminus.
[0127] The two fusion proteins can bind in the region of interest
in the same or opposite polarity, and their binding sites (i.e.,
target sites) can be separated by any number of nucleotides, e.g.,
from 0 to 200 nucleotides or any integral value therebetween. In
certain embodiments, the binding sites for two fusion proteins,
each comprising a zinc finger binding domain and a cleavage
half-domain, can be located between 5 and 18 nucleotides apart, for
example, 5-8 nucleotides apart, or 15-18 nucleotides apart, or 6
nucleotides apart, or 16 nucleotides apart, as measured from the
edge of each binding site nearest the other binding site, and
cleavage occurs between the binding sites.
[0128] The site at which the DNA is cleaved generally lies between
the binding sites for the two fusion proteins. Double-strand
breakage of DNA often results from two single-strand breaks, or
"nicks," offset by 1, 2, 3, 4, 5, 6 or more nucleotides, (for
example, cleavage of double-stranded DNA by native Fok I results
from single-strand breaks offset by 4 nucleotides). Thus, cleavage
does not necessarily occur at exactly opposite sites on each DNA
strand. In addition, the structure of the fusion proteins and the
distance between the target sites can influence whether cleavage
occurs adjacent a single nucleotide pair, or whether cleavage
occurs at several sites. However, for targeted integration,
cleavage within a range of nucleotides is generally sufficient, and
cleavage between particular base pairs is not required.
[0129] In the disclosed fusion proteins, the amino acid sequence
between the zinc finger domain and the cleavage domain (or cleavage
half-domain) is denoted the "ZC linker." The ZC linker is to be
distinguished from the inter-finger linkers discussed above. ZC
linkers are described in detail, for example, in International
Patent Publication No. WO 2007/014275.
[0130] As discussed in detail below, the fusion protein (ZFN), or a
polynucleotide encoding same, is introduced into a cell. Once
introduced into, or expressed in, the cell, the fusion protein
binds to the target sequence in PPP1R12C and cleaves within this
gene locus.
[0131] Targeted Integration into the PPP1R12C Gene
[0132] The disclosed methods and compositions can be used to cleave
DNA in the PPP1R12C gene of cellular chromatin, which facilitates
the stable, targeted integration of an exogenous sequence into the
"safe harbor" of the PPP1R12C locus. As noted above, loss of
function of endogenous PPP1R12C is well tolerated by human cells
and sequences integrated within this gene are broadly transcribed
from the endogenous promoter. Accordingly, PPP1R12C is a desirable
site for targeted integration of exogenous sequences.
[0133] For targeted integration into PPP1R12C, one or more zinc
finger binding domains are engineered to bind a target site at or
near the predetermined cleavage site, and a fusion protein
comprising the engineered zinc finger binding domain and a cleavage
domain is expressed in a cell. Upon binding of the zinc finger
portion of the fusion protein to the target site, the DNA is
cleaved, preferably via a double stranded break, near the target
site by the cleavage domain.
[0134] The presence of a double-stranded break in the PPP1R12C
locus facilitates integration of exogenous sequences via homologous
recombination. Thus, the polynucleotide comprising the exogenous
sequence to be inserted into the PPP1R12C gene will include one or
more regions of homology with PPP1R12C gene to facilitate
homologous recombination.
[0135] Any sequence of interest (exogenous sequence) can be
introduced into the PPP1R12C locus as described herein. Exemplary
exogenous sequences include, but are not limited to any polypeptide
coding sequence (e.g., cDNAs), promoter, enhancer and other
regulatory sequences, shRNA expression cassettes, epitope tags,
marker genes, cleavage enzyme recognition sites and various types
of expression constructs. Such sequences can be readily obtained
using standard molecular biological techniques (cloning, synthesis,
etc.) and/or are commercially available. For example, MISSION.TM.
TRC shRNA libraries are commercially available from Sigma.
[0136] Marker genes include, but are not limited to, sequences
encoding proteins that mediate antibiotic resistance (e.g.,
ampicillin resistance, neomycin resistance, G418 resistance,
puromycin resistance), sequences encoding colored or fluorescent or
luminescent proteins (e.g., green fluorescent protein, enhanced
green fluorescent protein, red fluorescent protein, luciferase),
cell surface antigens (e.g., .DELTA.NGFR) and proteins which
mediate enhanced cell growth and/or gene amplification (e.g.,
dihydrofolate reductase). Epitope tags include, for example, one or
more copies of FLAG, His, myc, Tap, HA or any detectable amino acid
sequence.
[0137] In a preferred embodiment, the exogenous sequence comprises
a polynucleotide encoding any polypeptide of which expression in
the cell is desired, including, but not limited to antibodies,
antigens, enzymes, receptors (cell surface or nuclear), hormones,
lymphokines, cytokines, reporter polypeptides, growth factors, and
functional fragments of any of the above. The coding sequences may
be, for example, cDNAs. The exogenous sequence may also encode
transcriptional regulatory factors.
[0138] For example, the exogenous sequence targeted to the PPP1R12C
locus comprises a sequence encoding a polypeptide that is lacking
or non-functional in the subject having a genetic disease,
including but not limited to any of the following genetic diseases:
achondroplasia, achromatopsia, acid maltase deficiency, adenosine
deaminase deficiency (OMIM No. 102700), adrenoleukodystrophy,
aicardi syndrome, alpha-1 antitrypsin deficiency,
alpha-thalassemia, androgen insensitivity syndrome, apert syndrome,
arrhythmogenic right ventricular, dysplasia, ataxia telangictasia,
barth syndrome, beta-thalassemia, blue rubber bleb nevus syndrome,
canavan disease, chronic granulomatous diseases (CGD), cri du chat
syndrome, cystic fibrosis, dercum's disease, ectodermal dysplasia,
fanconi anemia, fibrodysplasia ossificans progressive, fragile X
syndrome, galactosemis, Gaucher's disease, generalized
gangliosidoses (e.g., GM1), hemochromatosis, the hemoglobin C
mutation in the 6.sup.th codon of beta-globin (HbC), hemophilia,
Huntington's disease, Hurler Syndrome, hypophosphatasia,
Klinefleter syndrome, Krabbes Disease, Langer-Giedion Syndrome,
leukocyte adhesion deficiency (LAD, OMIM No. 116920),
leukodystrophy, long QT syndrome, Marfan syndrome, Moebius
syndrome, mucopolysaccharidosis (MPS), nail patella syndrome,
nephrogenic diabetes insipdius, neurofibromatosis, Neimann-Pick
disease, osteogenesis imperfecta, porphyria, Prader-Willi syndrome,
progeria, Proteus syndrome, retinoblastoma, Rett syndrome,
Rubinstein-Taybi syndrome, Sanfilippo syndrome, severe combined
immunodeficiency (SCID), Shwachman syndrome, sickle cell disease
(sickle cell anemia), Smith-Magenis syndrome, Stickler syndrome,
Tay-Sachs disease, Thrombocytopenia Absent Radius (TAR) syndrome,
Treacher Collins syndrome, trisomy, tuberous sclerosis, Turner's
syndrome, urea cycle disorder, von Hippel-Landau disease,
Waardenburg syndrome, Williams syndrome, Wilson's disease,
Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome
(XLP, OMIM No. 308240).
[0139] Additional exemplary diseases that can be treated by
targeted integration include acquired immunodeficiencies, lysosomal
storage diseases (e.g., Gaucher's disease, GM1, Fabry disease and
Tay-Sachs disease), mucopolysaccahidosis (e.g. Hunter's disease,
Hurler's disease), hemoglobinopathies (e.g., sickle cell diseases,
HbC, .alpha.-thalassemia, .beta.-thalassemia) and hemophilias.
[0140] In certain embodiments, the exogenous sequences can comprise
a marker gene (described above), allowing selection of cells that
have undergone targeted integration, and a linked sequence encoding
an additional functionality.
[0141] Furthermore, although not required for expression, exogenous
sequences may also be transcriptional or translational regulatory
sequences, for example, promoters, enhancers, insulators, internal
ribosome entry sites, sequences encoding 2A peptides and/or
polyadenylation signals.
[0142] Targeted integration of exogenous sequences, as disclosed
herein, can be used to generate cells and cell lines for protein
expression. See, for example, co-owned U.S. Patent Publication No.
2006/0063231 (the disclosure of which is hereby incorporated by
reference herein, in its entirety, for all purposes). For optimal
expression of one or more proteins encoded by exogenous sequences
integrated into a genome, the chromosomal integration site should
be compatible with high-level transcription of the integrated
sequences, preferably in a wide range of cell types and
developmental states. However, it has been observed that
transcription of integrated sequences varies depending on the
integration site due to, among other things, the chromatin
structure of the genome at the integration site. Accordingly,
genomic target sites that support high-level transcription of
integrated sequences are desirable. In certain embodiments, it will
also be desirable that integration of exogenous sequences not
result in ectopic activation of one or more cellular genes (e.g.,
oncogenes). On the other hand, in the case of integration of
promoter and/or enhancer sequences, ectopic expression may be
desired.
[0143] The exogenous (donor) sequence can be introduced into the
cell prior to, concurrently with, or subsequent to, expression of
the fusion protein(s). The donor polynucleotide contains sufficient
homology to a genomic sequence to support homologous recombination
(or homology-directed repair) between it and the genomic sequence
to which it bears homology. Approximately 25, 50, 100, 200, 500,
750, 1,000, 1,500, 2,000 nucleotides or more of sequence homology
between a donor and a genomic sequence (or any integral value
between 10 and 2,000 nucleotides, or more) will support homologous
recombination therebetween. Donor sequences can range in length
from 10 to 5,000 nucleotides (or any integral value of nucleotides
therebetween) or longer. It will be readily apparent that the donor
sequence is typically not identical to the genomic sequence that it
replaces. For example, the sequence of the donor polynucleotide can
contain one or more single base changes, insertions, deletions,
inversions or rearrangements with respect to the genomic sequence,
so long as sufficient homology with chromosomal sequences is
present.
[0144] Alternatively, a donor sequence can contain a non-homologous
sequence flanked by two regions of homology. Additionally, donor
sequences can comprise a vector molecule containing sequences that
are not homologous to the region of interest in cellular chromatin.
Generally, the homologous region(s) of a donor sequence will have
at least 50% sequence identity to a genomic sequence with which
recombination is desired. In certain embodiments, 60%, 70%, 80%,
90%, 95%, 98%, 99%, or 99.9% sequence identity is present. Any
value between 1% and 100% sequence identity can be present,
depending upon the length of the donor polynucleotide.
[0145] A donor molecule can contain several, discontinuous regions
of homology to cellular chromatin. For example, for regions of
homology can flank two or more regions containing the desired
alterations.
[0146] The donor polynucleotide can be DNA or RNA, single-stranded
or double-stranded and can be introduced into a cell in linear or
circular form. If introduced in linear form, the ends of the donor
sequence can be protected (e.g., from exonucleolytic degradation)
by methods known to those of skill in the art. See, International
Patent Publication No. WO 2007/014275. A polynucleotide can be
introduced into a cell as part of a vector molecule having
additional sequences such as, for example, replication origins,
promoters and genes encoding antibiotic resistance. Moreover, donor
polynucleotides can be introduced as naked nucleic acid, as nucleic
acid complexed with an agent such as a liposome or poloxamer, or
can be delivered by viruses (e.g., adenovirus, AAV, herpesvirus,
retrovirus, lentivirus).
[0147] Methods and compositions are also provided that may enhance
levels of targeted recombination including, but not limited to, the
use of additional ZFP-functional domain fusions. See, International
Patent Publication No. WO 2007/014275.
[0148] Further increases in efficiency of targeted recombination,
in cells comprising a zinc finger/nuclease fusion molecule and a
donor DNA molecule, are achieved by blocking the cells in the G2
phase of the cell cycle, when homology-driven repair processes are
maximally active. Such arrest can be achieved in a number of ways.
For example, cells can be treated with e.g., drugs, compounds
and/or small molecules which influence cell-cycle progression so as
to arrest cells in G2 phase. Exemplary molecules of this type
include, but are not limited to, compounds which affect microtubule
polymerization (e.g., vinblastine, nocodazole, Taxol), compounds
that interact with DNA (e.g., cis-platinum(II) diamine dichloride,
Cisplatin, doxorubicin) and/or compounds that affect DNA synthesis
(e.g., thymidine, hydroxyurea, L-mimosine, etoposide,
5-fluorouracil). Additional increases in recombination efficiency
are achieved by the use of histone deacetylase (HDAC) inhibitors
(e.g., sodium butyrate, trichostatin A) which alter chromatin
structure to make genomic DNA more accessible to the cellular
recombination machinery.
[0149] Additional methods for cell-cycle arrest include
overexpression of proteins which inhibit the activity of the CDK
cell-cycle kinases, for example, by introducing a cDNA encoding the
protein into the cell or by introducing into the cell an engineered
ZFP which activates expression of the gene encoding the protein.
Cell-cycle arrest is also achieved by inhibiting the activity of
cyclins and CDKs, for example, using RNAi methods (e.g., U.S. Pat.
No. 6,506,559) or by introducing into the cell an engineered ZFP
which represses expression of one or more genes involved in
cell-cycle progression such as, for example, cyclin and/or CDK
genes. See, e.g., co-owned U.S. Pat. No. 6,534,261 for methods for
the synthesis of engineered zinc finger proteins for regulation of
gene expression.
[0150] Alternatively, in certain cases, targeted cleavage is
conducted in the absence of a donor polynucleotide (preferably in S
or G2 phase), and recombination occurs between homologous
chromosomes.
[0151] Delivery
[0152] The fusion protein(s) (ZFNs) can be introduced as
polypeptides and/or polynucleotides. For example, two
polynucleotides, each comprising sequences encoding one of the
aforementioned polypeptides, can be introduced into a cell, and
when the polypeptides are expressed and each binds to its target
sequence, cleavage occurs at or near the target sequence.
Alternatively, a single polynucleotide comprising sequences
encoding both fusion polypeptides is introduced into a cell.
Polynucleotides can be DNA, RNA or any modified forms or analogues
or DNA and/or RNA.
[0153] The nucleic acids as described herein (e.g., a
polynucleotide encoding ZFN and/or the exogenous "donor" sequence)
may be introduced into a cell using any suitable method.
[0154] In certain embodiments, one or more ZFPs or ZFP fusion
proteins can be cloned into a vector for transformation into
prokaryotic or eukaryotic cells for replication and/or expression.
Vectors can be prokaryotic vectors, e.g., plasmids, or shuttle
vectors, insect vectors, or eukaryotic vectors. A nucleic acid
encoding sequences described herein (ZFNs) can also be cloned into
an expression vector, for administration to a plant cell, animal
cell, preferably a mammalian cell or a human cell, fungal cell,
bacterial cell, or protozoal cell using standard techniques
described for example in Sambrook et al., supra and U.S. Patent
Publication Nos. 2003/0232410; 2005/0208489; 2005/0026157;
2005/0064474; and 2006/0188987, and International Patent
Publication No. WO 2007/014275.
[0155] In certain embodiments, the ZFNs and donor sequences are
delivered in vivo or ex vivo for gene therapy uses. Non-viral
vector delivery systems for delivering polynucleotides to cells
include DNA plasmids, naked nucleic acid, and nucleic acid
complexed with a delivery vehicle such as a liposome or poloxamer.
Viral vector delivery systems include DNA and RNA viruses, which
have either episomal or integrated genomes after delivery to the
cell. For a review of gene therapy procedures, see Anderson,
Science 256:808-813 (1992); Nabel & Felgner, TIBTECH 11:211-217
(1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon,
TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van
Brunt, Biotechnology 6(10):1149-1154 (1988); Vigne, Restorative
Neurology and Neuroscience 8:35-36 (1995); Kremer &
Perricaudet, British Medical Bulletin 51(1):31-44 (1995); Haddada
et al., in Current Topics in Microbiology and Immunology Doerfler
and Bohm (eds.) (1995); and Yu et al., Gene Therapy 1:13-26
(1994).
[0156] Methods of non-viral delivery of nucleic acids in vivo or ex
vivo include electroporation, lipofection (see, U.S. Pat. Nos.
5,049,386 and 4,946,787 and commercially available reagents such as
Transfectam.TM. and Lipofectin.TM.) microinjection, biolistics,
virosomes, liposomes (see, e.g., Crystal, Science 270:404-410
(1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et
al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate
Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995);
Ahmad et al., Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos.
4,186,183; 4,217,344; 4,235,871; 4,261,975; 4,485,054; 4,501,728;
4,774,085; 4,837,028; and 4,946,787), immunoliposomes, polycation
or lipid:nucleic acid conjugates, naked DNA, artificial virions,
viral vector systems (e.g., retroviral, lentivirus, adenoviral,
adeno-associated, vaccinia and herpes simplex virus vectors as
described in International Patent Publication No. WO 2007/014275
for delivering proteins comprising ZFPs) and agent-enhanced uptake
of DNA. Sonoporation using, e.g., the Sonitron 2000 system
(Rich-Mar) can also be used for delivery of nucleic acids.
[0157] Additional exemplary nucleic acid delivery systems include
those provided by Amaxa Biosystems (Cologne, Germany), Maxcyte,
Inc. (Rockville, Md.) and BTX Molecular Delivery Systems
(Holliston, Mass.).
[0158] In certain embodiments, for example, in which transient
expression of a ZFP fusion protein is preferred, adenoviral based
systems can be used. Adenoviral based vectors are capable of very
high transduction efficiency in many cell types and do not require
cell division. With such vectors, high titer and high levels of
expression have been obtained. This vector can be produced in large
quantities in a relatively simple system. Adeno-associated virus
("AAV") vectors are also used to transduce cells with target
nucleic acids, e.g., in the in vitro production of nucleic acids
and peptides, and for in vivo and ex vivo gene therapy procedures
(see, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No.
4,797,368; International Patent Publication No. WO 93/24641; Kotin,
Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest.
94:1351 (1994). Construction of recombinant AAV vectors are
described in a number of publications, including U.S. Pat. No.
5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985);
Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat
& Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J.
Virol. 63:03822-3828 (1989).
[0159] At least six viral vector approaches are currently available
for gene transfer in clinical trials, which utilize approaches that
involve complementation of defective vectors by genes inserted into
helper cell lines to generate the transducing agent.
[0160] pLASN and MFG-S are examples of retroviral vectors that have
been used in clinical trials (Dunbar et al., Blood 85:3048-305
(1995); Kohn et al., Nat. Med. 1:1017-102 (1995); Malech et al.,
PNAS 94:22 12133-12138 (1997)). PA317/pLASN was the first
therapeutic vector used in a gene therapy trial. (Blaese et al.,
Science 270:475-480 (1995)). Transduction efficiencies of 50% or
greater have been observed for MFG-S packaged vectors. (Ellem et
al., Immunol Immunother 44(1):10-20 (1997); Dranoff et al., Hum.
Gene Ther. 1:111-2 (1997).
[0161] Recombinant adeno-associated virus vectors (rAAV) are a
promising alternative gene delivery systems based on the defective
and nonpathogenic parvovirus adeno-associated virus subtypes. All
vectors are derived from a plasmid that retains only the AAV 145 bp
inverted terminal repeats flanking the transgene expression
cassette. Efficient gene transfer and stable transgene delivery due
to integration into the genomes of the transduced cell are key
features for this vector system. (Wagner et al., Lancet 351:9117
1702-3 (1998), Kearns et al., Gene Ther. 9:748-55 (1996)). In
addition, self complementary recombinant adeno-associated virus
(scAAV)-derived vectors can be used.
[0162] Replication-deficient recombinant adenoviral vectors (Ad)
can be produced at high titer and readily infect a number of
different cell types. Most adenovirus vectors are engineered such
that a transgene replaces the Ad E1a, E1b, and/or E3 genes;
subsequently the replication defective vector is propagated in
human 293 cells that supply deleted gene function in trans. Ad
vectors can transduce multiple types of tissues in vivo, including
nondividing, differentiated cells such as those found in liver,
kidney and muscle. Conventional Ad vectors have a large carrying
capacity. An example of the use of an Ad vector in a clinical trial
involved polynucleotide therapy for antitumor immunization with
intramuscular injection (Sterman et al., Hum. Gene Ther. 7:1083-9
(1998)). Additional examples of the use of adenovirus vectors for
gene transfer in clinical trials include Rosenecker et al.,
Infection 24:1 5-10 (1996); Sterman et al., Hum. Gene Ther. 9:7
1083-1089 (1998); Welsh et al., Hum. Gene Ther. 2:205-18 (1995);
Alvarez et al., Hum. Gene Ther. 5:597-613 (1997); Topf et al., Gene
Ther. 5:507-513 (1998); Sterman et al., Hum. Gene Ther. 7:1083-1089
(1998).
[0163] Packaging cells are used to form virus particles that are
capable of infecting a host cell. Such cells include 293 cells,
which package adenovirus, and .psi.2 cells or PA317 cells, which
package retrovirus. Viral vectors used in gene therapy are usually
generated by a producer cell line that packages a nucleic acid
vector into a viral particle. The vectors typically contain the
minimal viral sequences required for packaging and subsequent
integration into a host (if applicable), other viral sequences
being replaced by an expression cassette encoding the protein to be
expressed. The missing viral functions are supplied in trans by the
packaging cell line. For example, AAV vectors used in gene therapy
typically only possess inverted terminal repeat (ITR) sequences
from the AAV genome which are required for packaging and
integration into the host genome. Viral DNA is packaged in a cell
line, which contains a helper plasmid encoding the other AAV genes,
namely rep and cap, but lacking ITR sequences. The cell line is
also infected with adenovirus as a helper. The helper virus
promotes replication of the AAV vector and expression of AAV genes
from the helper plasmid. The helper plasmid is not packaged in
significant amounts due to a lack of ITR sequences. Contamination
with adenovirus can be reduced by, e.g., heat treatment to which
adenovirus is more sensitive than AAV.
[0164] In many gene therapy applications, it is desirable that the
polynucleotides (e.g., ZFN-encoding sequence and/or donor
sequences) be delivered with a high degree of specificity to a
particular tissue type. Accordingly, a viral vector can be modified
to have specificity for a given cell type by expressing a ligand as
a fusion protein with a viral coat protein on the outer surface of
the virus. The ligand is chosen to have affinity for a receptor
known to be present on the cell type of interest. For example, Han
et al., Proc. Natl. Acad. Sci. USA 92:9747-9751 (1995), reported
that Moloney murine leukemia virus can be modified to express human
heregulin fused to gp70, and the recombinant virus infects certain
human breast cancer cells expressing human epidermal growth factor
receptor. This principle can be extended to other virus-target cell
pairs, in which the target cell expresses a receptor and the virus
expresses a fusion protein comprising a ligand for the cell-surface
receptor. For example, filamentous phage can be engineered to
display antibody fragments (e.g., FAB or Fv) having specific
binding affinity for virtually any chosen cellular receptor.
Although the above description applies primarily to viral vectors,
the same principles can be applied to nonviral vectors. Such
vectors can be engineered to contain specific uptake sequences
which favor uptake by specific target cells.
[0165] Gene therapy vectors can be delivered in vivo by
administration to an individual patient, typically by systemic
administration (e.g., intravenous, intraperitoneal, intramuscular,
subdermal, or intracranial infusion) or topical application, as
described below. Alternatively, vectors can be delivered to cells
ex vivo, such as cells explanted from an individual patient (e.g.,
lymphocytes, bone marrow aspirates, tissue biopsy) or universal
donor hematopoietic stem cells, followed by reimplantation of the
cells into a patient, usually after selection for cells which have
incorporated the vector.
[0166] Ex vivo cell transfection for diagnostics, research, or for
gene therapy (e.g., via re-infusion of the transfected cells into
the host organism) is well known to those of skill in the art. In a
preferred embodiment, cells are isolated from the subject organism,
transfected with a ZFP nucleic acid (gene or cDNA) and exogenous
sequence, and re-infused back into the subject organism (e.g.,
patient). Various cell types suitable for ex vivo transfection are
well known to those of skill in the art (see, e.g., Freshney et
al., Culture of Animal Cells, A Manual of Basic Technique (3rd ed.
1994)) and the references cited therein for a discussion of how to
isolate and culture cells from patients).
[0167] In one embodiment, stem cells are used in ex vivo procedures
for cell transfection and gene therapy. The advantage to using stem
cells is that they can be differentiated into other cell types in
vitro, or can be introduced into a mammal (such as the donor of the
cells) where they will engraft in the bone marrow. Methods for
differentiating CD34+ cells in vitro into clinically important
immune cell types using cytokines such a GM-CSF, IFN-.gamma. and
TNF-.alpha. are known (see Inaba et al., J. Exp. Med. 176:1693-1702
(1992)).
[0168] Stem cells are isolated for transduction and differentiation
using known methods. For example, stem cells are isolated from bone
marrow cells by panning the bone marrow cells with antibodies which
bind unwanted cells, such as CD4+ and CD8+(T cells), CD45+(panB
cells), GR-1 (granulocytes), and Tad (differentiated antigen
presenting cells) (see Inaba et al., J. Exp. Med. 176:1693-1702
(1992)).
[0169] Vectors (e.g., retroviruses, adenoviruses, liposomes, etc.)
comprising nucleic acids as described herein can also be
administered directly to an organism for transduction of cells in
vivo. Alternatively, naked DNA can be administered. Administration
is by any of the routes normally used for introducing a molecule
into ultimate contact with blood or tissue cells including, but not
limited to, injection, infusion, topical application and
electroporation. Suitable methods of administering such nucleic
acids are available and well known to those of skill in the art,
and, although more than one route can be used to administer a
particular composition, a particular route can often provide a more
immediate and more effective reaction than another route.
[0170] Methods for introduction of DNA into hematopoietic stem
cells are disclosed, for example, in U.S. Pat. No. 5,928,638.
Vectors useful for introduction of transgenes into hematopoietic
stem cells, e.g., CD34.sup.+ cells, include adenovirus Type 35.
[0171] Vectors suitable for introduction of transgenes into immune
cells (e.g., T-cells) include non-integrating lentivirus vectors.
See, for example, Ory et al. (1996) Proc. Natl. Acad. Sci. USA
93:11382-11388; Dull et al. (1998) J. Virol. 72:8463-8471; Zuffery
et al. (1998) J. Virol. 72:9873-9880; Follenzi et al. (2000) Nature
Genetics 25:217-222.
[0172] Pharmaceutically acceptable carriers are determined in part
by the particular composition being administered, as well as by the
particular method used to administer the composition. Accordingly,
there is a wide variety of suitable formulations of pharmaceutical
compositions available, as described below (see, e.g., Remington's
Pharmaceutical Sciences, 17th ed., 1989).
[0173] As noted above, one or more of the ZFN fusion proteins can
be also be introduced into the cell as polypeptides using methods
described for example in International Patent Publication No. WO
2007/014275. Non-limiting examples of protein delivery vehicles
include, "membrane translocation polypeptides," for example peptide
have amphiphilic or hydrophobic amino acid subsequences that have
the ability to act as membrane-translocating carriers, toxin
molecules, liposomes and liposome derivatives such as
immunoliposomes (including targeted liposomes).
[0174] ZFPs and expression vectors encoding ZFPs can be
administered directly to the patient for targeted cleavage
integration into PPP1R12C for therapeutic or prophylactic
applications, for example, cancer, ischemia, diabetic retinopathy,
macular degeneration, rheumatoid arthritis, psoriasis, HIV
infection, sickle cell anemia, Alzheimer's disease, muscular
dystrophy, neurodegenerative diseases, vascular disease, cystic
fibrosis, stroke, and the like.
[0175] Administration of therapeutically effective amounts is by
any of the routes normally used for introducing ZFP into ultimate
contact with the tissue to be treated. The ZFPs are administered in
any suitable manner, preferably with pharmaceutically acceptable
carriers. Suitable methods of administering such modulators are
available and well known to those of skill in the art, and,
although more than one route can be used to administer a particular
composition, a particular route can often provide a more immediate
and more effective reaction than another route.
[0176] Pharmaceutically acceptable carriers are determined in part
by the particular composition being administered, as well as by the
particular method used to administer the composition. Accordingly,
there is a wide variety of suitable formulations of pharmaceutical
compositions that are available (see, e.g., Remington's
Pharmaceutical Sciences, 17.sup.th ed. 1985)).
[0177] The ZFPs, alone or in combination with other suitable
components, can be made into aerosol formulations (i.e., they can
be "nebulized") to be administered via inhalation. Aerosol
formulations can be placed into pressurized acceptable propellants,
such as dichlorodifluoromethane, propane, nitrogen, and the
like.
[0178] Formulations suitable for parenteral administration, such
as, for example, by intravenous, intramuscular, intradermal, and
subcutaneous routes, include aqueous and non-aqueous, isotonic
sterile injection solutions, which can contain antioxidants,
buffers, bacteriostats, and solutes that render the formulation
isotonic with the blood of the intended recipient, and aqueous and
non-aqueous sterile suspensions that can include suspending agents,
solubilizers, thickening agents, stabilizers, and preservatives.
The disclosed compositions can be administered, for example, by
intravenous infusion, orally, topically, intraperitoneally,
intravesically or intrathecally. The formulations of compounds can
be presented in unit-dose or multi-dose sealed containers, such as
ampules and vials. Injection solutions and suspensions can be
prepared from sterile powders, granules, and tablets of the kind
previously described.
EXAMPLES
Example 1: Design of Zinc Finger Nucleases Targeted to PPP1R12C
[0179] Fusion proteins comprising a pair of 4-fingered zinc finger
protein nucleases (ZFNs) were designed as described in
International Publication WO 2007/014275 and optimized optimized
using phage display according to published protocols (Rebar &
Pabo (1994) Science 263(5147):671-3; Greisman & Pabo (1997)
Science 275(5300):657-61) to induce a double stranded break into
intron 1 of PPP1R12C as shown in FIG. 1. The ZFN target sequence
corresponds to positions 60318932-60318961 of the "-" strand of
human chromosome 19 (UCSC human genome release March 2006).
[0180] Table 1 shows exemplary PPP1R12C-targeted ZFNs were that
used for targeted integration experiments into the PPP1R12C
locus.
TABLE-US-00001 TABLE 1 ZFN name Target Site F1 F2 F3 F4 9931
acTAGGGACAGGATtg QSSNLAR RPDFLNQ QSGHLAR RSDNLTT (SEQ ID NO: 1)
(SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 3) NO: 4) NO: 5) NO: 6) 10099
ccCCACTGTGGGGTgg QSSHLTR RSDHLTT HNYARDC QKATRTT (SEQ ID NO: 2)
(SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 7) NO: 8) NO: 9) NO: 10) 15587
acTAGGGACAGGATtg QSSNLAR RTDYLVD YNTHLTR RSDNLTT (SEQ ID NO: 1)
(SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 3) NO: 11) NO: 12) NO: 6) 15590
acTAGGGACAGGATtg QSSNLAR RTDYLVD YNTHLTR QGYNLAG (SEQ ID NO: 1)
(SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 3) NO: 11) NO: 12) NO: 13)
15554 ccCCACTGTGGGGTgg ERHHLMR RSDHLTT HNYARDC QNSTRIG (SEQ ID NO:
2) (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 14) NO: 8) NO: 9) NO: 15)
15556 ccCCACTGTGGGGTgg YNWHLQR RSDHLTT HNYARDC QNSTRIG (SEQ ID NO:
2) (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 16) NO: 8) NO: 9) NO: 15)
15557 ccCCACTGTGGGGTgg LHHQLVR RSDHLTT HNYARDC QNSTRIG (SEQ ID NO:
2) (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 17) NO: 8) NO: 9) NO:
15)
Example 2: Targeted Integration into PPP1R12C Locus
[0181] A donor was designed by using a 1,647 bp fragment of the
same locus (positions 60318104-60319750), and introducing a "splice
acceptor-FMDV 2A-GFP-poly(A)" cassette into the position between
the ZFN 9931 AND 10099 binding sites. The ZFN and donor constructs
were prepared as described in Urnov et al. (2005) Nature
435:646-651 and Moehle et al. (2007) PNAS 194:305, except that
obligate heterodimer forms of the FokI endonuclease were used in
the ZFN expression constructs (see, Section entitled "Cleavage
Domains" above) and introduced into K562, 293T, Hep3B or HEK293
cells.
[0182] Seventy two hours after transfection, the rate of targeted
integration (TI) was assayed by a radiolabelled PCR assay, as
described Moehle et al. (2007) Proc. Nat'l Acad. Sci. USA
104:3055-3060. Two weeks after transfection, the percentage of
GFP-positive cells was assayed by FACS, also as described Moehle et
al. (2007).
[0183] Results are shown in FIGS. 3 and 4. Targeted integration
frequency analysis (FIGS. 3A and B) demonstrated that integration
of donor sequences into PPP1R12C was significantly increased in the
presence of the ZFNs in both K562 (FIG. 3A) and 293T (FIG. 3B)
cells. The results of the PCR analysis were verified by Southern
blotting (see FIG. 7B).
[0184] Furthermore, as shown in FIG. 4, GFP expression by FACS
analysis also confirmed that the GFP donor sequence was integrated
into PPP1R12C. In particular, the donor GFP sequence integration
frequency into PPP1R12C (FIG. 4A) without co-introduction of the
ZFN expression construct was negligible. In the presence of the
ZFNs, the percent of cells in which the donor sequence was
integrated into the target site in PPP1R12C increased to 13.09%
(FIG. 4B). Likewise, in 293T cells, the donor sequence was not
integrated in wild-type cells (FIG. 4C, 0%) but was integrated in
3.66% of cells in the presence of PPP1R12C-targeted ZFNs (FIG. 4D).
In Hep3B cells, the donor sequence integrated into 0.65% cells in
the absence of PPP1R12C-targeted ZFNs (FIG. 4E) but was integrated
into 1.73% of Hep3B cells in the presence of PPP1R12C-targeted ZFNs
(FIG. 4F).
[0185] Thus, in a variety of cell types, ZFNs drove targeted
integration of a promoterless exogenous coding sequence into the
PPP1R12C "safe harbor" locus.
Example 3: Quantitative RT-PCR Measurement of PPP1R12C/p84 mRNA
[0186] Quantitative RT-PCR measurement of PPP1R12C/p84 mRNA levels
across a panel of commonly used transformed cell types (HEK293
(293T), fibroblasts, K562, HeLa, DU-145, Hep3B) was done to
investigate if the gene was expressed in a variety of cell types.
Results are presented as the ratio of expression of the PPP121R12C
locus relative to either 18S or GAPDH. Briefly, levels of PPP1R12C
mRNA were measured by real-time RT-PCR on an Applied Biosystems
7300 TaqMan machine as described in Tan et al. (2003) Proc. Nat'l
Acad. Sci. USA 100:11997-12002), using a custom-made gene
expression assay (ABI) for PPP1R12C. The results, shown in FIG. 5,
demonstrated that PPP1R12C/p84 is broadly transcribed, in
conformance with available data indicating that PPP1R12C/p84 is
constitutively transcribed in all human cells/tissues studied.
Example 4: Targeted Integration into PPP1R12C Locus
[0187] To determine the utility of the PPP1R12C (p84) gene locus
for gene addition, lead ZFNs from the panel of ZFNs shown in Table
1 were identified via a screen employing transient transfection of
a panel of alternative ZFN designs and the Surveyor Nuclease Assay
to determine the efficiency of DSB induction (Miller et al. (2007)
Nat Biotechnol. 25(7):778-85). This assay measures the fraction of
PPP1R12C/p84-derived chromatids carrying the genetic signature of
DSB repair: small insertions and deletions generated by
non-homologous end-joining. For all experiments on targeted
integration into PPP1R12C/p84, we used a 1.6 kb donor DNA construct
homologous to the chromosomal locus (Urnov et al., Nature 2005
435(7042):646-51), and introduced heterologous stretches described
using standard recombinant DNA techniques. An autonomous expression
cassette for the .DELTA.LNGFR cell surface marker was introduced
outside the right homology arm of the donor construct using a
unique SnaBI site. HEK293 and K562 cells were cultured and
transfected with DNA constructs as described in Urnov et al.
(ibid).
[0188] As shown in FIG. 6, all ZFN pairs tested integrated the
donor construct, as compared to the negative control which showed
no integration. These data demonstrated that ZFNs efficiently
targeting a DSB into the desired region of PPP1R12C/p84 gene locus
have been obtained.
[0189] In addition, the lead ZFN pair (15556/15590, lane 5 of FIG.
6) identified in this assay introduced a DSB .about.1,800 bp
downstream of the transcription start site of the PPP1R12C/p84 gene
i.e. sufficiently distant from the native promoter sequences to
permit a promoter-free donor DNA design for the addition of an open
reading frame to this locus (FIG. 7A). We have shown previously
that optimization of the ZFPs targeting a DNA site increases genome
editing rates. See, e.g., Urnov et al. (2005). In agreement with
this observation, optimization of the lead ZFNs for PPP1R12C/p84
also resulted in a marked enhancement (.about.4-fold increase) in
cleavage activity resulting in a population of transiently
transfected K562 cells displaying one edited chromatid in five.
Example 5: ZFN-Mediated Site-Specific Gene Addition
[0190] To determine whether the ZFNs above would drive efficient
site-specific addition of a gene cassette into the PPP1R12C/p84
locus, we used a promoterless donor DNA design that exploited the
native PPP1R12C/p84 promoter to yield a marker-positive cell (FIG.
7a). This donor plasmid includes two 750 bp stretches of sequence
homologous to the region flanking the DSB site in intron 1 of the
PPP1R12C/p84 locus interrupted by a promoterless GFP ORF and
polyadenylation signal sequence. As exon 1 of PPP1R12C/p84 is
translated, to achieve native PPP1R12C/p84 promoter driven GFP
expression we included a splice acceptor site followed by the 2A
ribosome stuttering signal (see, Fang et al. (2005) Nat Biotech.
23:584), upstream of the ORF (FIG. 7A).
[0191] As depicted in FIG. 7A, bona fide site-specific gene
addition of this cassette into the PPP1R12C/p84 locus would result
in a single transcript driven from the PPP1R12C/p84 promoter that
includes exon 1 of PPP1R12C/p84 and the marker GFP ORF. Translation
of this mRNA would result in the generation of 2 separate
polypeptides as a result of the 2A peptide sequence; (i) the
peptide encoded by exon 1 of PPP1R12C/p84; and (ii) a complete GFP
polypeptide. FACS analysis was performed using a bench top
mini-FACS device (Guava Technologies) and the data was further
analyzed using the WinMDI software. DNA-based analysis of targeted
integration frequency was performed by a highly quantitative PCR
assay as described (Urnov et al., 2005), except the restriction
enzyme digestion step was omitted (the sole exception being
experiments with a donor that introduces a 30 bp patch that
contains a NcoI recognition site, in which the small size
difference between a wild-type and integrant-carrying chromosome
necessitated the use of restriction enzyme digestion). Southern
blotting on genomic DNA digested with DpnI to eliminate excess
donor DNA and AccI to digest the genomic DNA was performed as
described (Urnov et al., 2005). Genome-wide expression profiling
and immunocytochemistry were performed as described essentially in
Miller et al. (2007) Nat. Biotechnol. 25(7):778-785 and Tan et al.
(2003) Proc Natl Acad Sci USA 100:11997-12002.
[0192] Analysis of K562 cells 48 hrs post-transfection with plasmid
DNAs encoding the ZFN and donor DNA constructs demonstrated that,
on average, 10% of chromatids in the cell population had acquired
the donor-specified cassette as gauged by PCR and by Southern
blotting (FIG. 7B). The modified cells were then grown for a month
(over 30 population doublings), in the absence of any selection.
Consistent with the molecular data obtained at day 2 (FIG. 7B, lane
2), and despite an extended period in culture, 13% GFP-positive
cells were observed in the ZFN and donor treated pool, while less
than 1% of the cells treated with the donor plasmid alone expressed
GFP. These data show that addition of a promotorless marker ORF to
the human PPP1R12C/p84 locus yields a high frequency of stably
marker-positive cells in the absence of selection for the desired
event.
[0193] To determine the generality of these observations, we
conducted an analogous experiment with two additional commonly used
cell types of distinct derivation (HEK293, a cell line obtained by
adenovirus transformation of neuronal cells, and Hep3B, a
hepatocellular carcinoma). Noting that the endogenous PPP1R12C/p84
promoter is active both these cell types, we used the same
promotorless GFP donor plasmid as before (FIG. 7A, top panel) and
were able to obtain pools of GFP-positive cells carrying a
ZFN-added ORF at the PPP1R12C/p84 4 locus. Notably, other than the
use of transient transfection conditions specific for the cell type
of interest, no other modification was necessary for the reagents
to perform GFP ORF addition.
[0194] Taken together, these data demonstrate that ZFN-mediated
site-specific stable gene addition to the PPP1R12C/p84 gene locus
can be rapidly achieved by simple transient transfection of
appropriate plasmid DNAs across a panel of commonly used human
cells.
Example 6: Gene Addition to PPP1R12C/p84 Results in Stable
Expression Levels
[0195] Transgenesis via random integration of foreign DNA via
plasmid or viral delivery often results in variable initial gene
expression levels as well as instability of expression over
time.
[0196] To determine whether ZFN-mediated site specific gene
addition to the PPP1R12C/p84 locus would overcome these
limitations, we exposed K562 cells to the ZFN and GFP ORF-encoding
plasmids, expanded the cells in the absence of any selective agent
for 4 weeks, and then used FACS to isolate the GFP-positive cell
pool. PCR amplification of the larger (transgene-containing)
chromatid is less efficient than that of the smaller, wild-type
allele in a mixed cell population. Normalizing for this difference
we genotyped the PPP1R12C/p84 locus in these cells by PCR, which
revealed that .about.80% of the chromatids carry the inserted ORF
at the PPP1R12C/p84 gene locus (FIG. 8E, lane 2). Importantly,
limiting dilution without additional sorting for GFP expression
generated a panel of .about.20 single cell-derived clonal lines
found carry the precise insertion of the GFP cassette at
PPP1R12C/p84 in a monoallelic or diallelic configuration, and at a
relative frequency fully consistent with results of the PCR
genotyping.
[0197] In addition, sequence-based genotyping of the transgenic
chromatids revealed the precise, homology-based addition of the
donor-specified transgene to the PPP1R12C/p84 locus.
[0198] To determine the stability of GFP expression, representative
control K562 cells, the GFP-positive FACS enriched cell pool, and
two single-cell clonal lines, monoallelic and diallelic for GFP
insertion at PPP1R12C/p84, were grown for 50 cell doublings, and
assayed for GFP expression level biweekly. The data, shown in FIG.
8A, revealed (i) no loss of mean fluorescence intensity over course
of the experiment; (ii) no change in the overall fraction of
marker-negative cells in the GFP-positive cell pool (.about.5%);
and (iii) a consistently higher mean fluorescence intensity of
cells homozygous for the GFP cassette at PPP1R12C/p84 than
heterozygous.
[0199] These data demonstrate that ZFN-enabled ORF addition to the
PPP1R12C/p84 gene locus results in the long-term stability and
consistency of expression expected from engineering an "endogenous
promoter trap."
Example 7: ZFN-Driven Addition of an Autonomous Expression
Cassette
[0200] To extend the results obtained with the promoterless GFP ORF
system for marker expression driven by the PPP1R12C/p84 promoter
(FIG. 7), we next evaluated the feasibility of using a donor DNA
design that encodes an autonomous expression cassette: this
so-called "promoter-transcription unit" (PTU) carries its own
promoter, followed by a stretch to be transcribed (such as a
shRNA-encoding construct or a cDNA), and a transcription
termination signal (e.g., a poly(A) stretch or an RNA polymerase
III terminator). We modified our donor plasmid to contain an
expression cassette for an shRNA. This donor DNA design is shown in
schematic form in FIG. 8B. We chose to retain the elements of
promoterless GFP ORF system as a method of tagging cells that have
undergone bona fide gene addition to the PPP1R12C/p84 locus.
Downstream of the GFP cassette we included a shRNA expression
cassette targeting the cell surface marker CD58, (known to be
expressed in K562 cells), thus physically linking GFP expression
(driven from PPP1R12C/p84) to the integration of the shRNA
expression construct at the same locus.
[0201] Quantitative PCR analysis 48 hrs post-transfection of K562
cells with the ZFNs and the shRNA-containing donor plasmid revealed
8% of the PPP1R12C/p84 chromatids to have acquired the ORF-PTU
cassette at the target site. FACS sorting of the GFP-positive cell
pool resulted in a .about.10-fold enrichment in ZFN-modified
chromatids (FIG. 8D).
[0202] To determine the efficacy of the inserted shRNA cassette we
compared control cells and PPP1R12C/p84 ZFN/donor modified cells by
FACS staining for CD58, the target of the shRNA molecule.
Importantly, cell-surface staining for CD58 was significantly
reduced even after 30 cell population doublings and was comparable
in magnitude to that seen 48 hrs post-transient transfection with
the shRNA expression plasmid itself. See, FIG. 8C. It is noteworthy
that the 48 hr, transient-transfection sample demonstrates target
gene reduction comparable to that seen in cells carrying only 1 or
2 copies in a stably transgenic setting. Parallel generation of a
pool of ZFN-modified cells using the GFP only donor (i.e.
site-specific gene addition but no shRNA cassette) resulted in
normal levels of CD58 staining, while a control sample in which the
CD58 antibody was omitted provided for only residual
fluorescence.
[0203] Taken together, these data demonstrate the utility of the
promoterless GFP-linked PTU donor system for the rapid,
drug-selection-free, single-step tagging and isolation of a cell
population transgenic at a specific site for a stably expressed
PTU.
Example 8: Specificity of ZFN-Driven PPP1R12C/p84 Gene
Targeting
[0204] We used two well-established assays to experimentally
investigate the specificity of ZFN-driven gene addition using
plasmid based delivery.
[0205] First, we measured the generation of DSBs genome-wide using
a well-studied hallmark of DSB repair, namely the assembly of a
focus of phosphorylated histone variant H2A.X at the repair site
(Paull et al. (2000) Curr Biol 10:886-895). We conducted these
assays conducted in parallel with positive control ZFNs (targeting
the IL2R.gamma. locus). The PPP1R12C/p84- and IL2R.gamma.-targeting
ZFN employ high-fidelity "obligate heterodimer" forms of the FokI
endonuclease, designed to limit the action of the pair of ZFNs to
their required target. See, Miller et al. (2007) Nat. Biotechnol.
25(7):778-785. In the case of these IL2R.gamma.-targeting ZFNs this
results in proteins that generate only a single DSB above
background in the whole nucleus.
[0206] Despite being .about.2.5.times. more effective at editing
their intended target site, the PPP1R12C/p84 ZFNs showed
statistically indistinguishable levels of H2A.X staining from those
obtained with the IL2R.gamma.-targeting ZFNs. See, FIGS. 9A and 9B.
In contrast, treatment with the DSB-inducing drug etoposide
resulted in a statistically significant increase in H2A.X signal,
thus confirming assay functionality.
[0207] Second, we asked whether the expression of the PPP1R12C/p84
ZFNs would increase the rate at which the donor DNA became randomly
integrated into the genome. To address this question, we used a
plasmid donor DNA carrying an autonomous expression cassette for a
cell surface marker (.DELTA.NGFR) placed outside the donor homology
arms, essentially as described in Moehle et al. (2007).
Misintergation of the plasmid would result in the incorporation and
expression of the .DELTA.NGFR cassette, which homology-directed
repair results in GFP positive cells without .DELTA.NGFR
expression.
[0208] In agreement with earlier work examining the ZFNs targeted
to the IL2R.gamma. locus (Moehle et al., 2007; Urnov et al., 2005),
we found no increase in donor plasmid misintegration rate above
that observed in cells treated with the donor DNA only. In
contrast, the addition of etoposide (a DNA damage inducing drug)
lead to a statistically significant increase in the number of
.DELTA.NGFR cells.
[0209] These data indicate that the PPP1R12C/p84-directed nucleases
do not, within the limit of sensitivity of the assays used,
generate more than a single DSB above background, nor drive a
measurable increase in donor plasmid random integration. Thus, in
two assays of ZFN specificity--a direct measurement of the number
of ZFN-induced DSBs per genome and an indirect readout via random
integration--the PPP1R12C/p84 ZFNs demonstrated high specificity,
supporting their use in the generation of transformed human cell
lines.
[0210] All patents, patent applications and publications mentioned
herein are hereby incorporated by reference, in their entireties,
for all purposes.
[0211] Although disclosure has been provided in some detail by way
of illustration and example for the purposes of clarity of
understanding, it will be apparent to those skilled in the art that
various changes and modifications can be practiced without
departing from the spirit or scope of the disclosure. Accordingly,
the foregoing descriptions and examples should not be construed as
limiting.
Sequence CWU 1
1
19116DNAArtificial SequenceSynthetic oligonucleotide 1actagggaca
ggattg 16216DNAArtificial SequenceSynthetic oligonucleotide
2ccccactgtg gggtgg 1637PRTArtificial SequenceSynthetic peptide 3Gln
Ser Ser Asn Leu Ala Arg 1 5 47PRTArtificial SequenceSynthetic
peptide 4Arg Pro Asp Phe Leu Asn Gln 1 5 57PRTArtificial
SequenceSynthetic peptide 5Gln Ser Gly His Leu Ala Arg 1 5
67PRTArtificial SequenceSynthetic peptide 6Arg Ser Asp Asn Leu Thr
Thr 1 5 77PRTArtificial SequenceSynthetic peptide 7Gln Ser Ser His
Leu Thr Arg 1 5 87PRTArtificial SequenceSynthetic peptide 8Arg Ser
Asp His Leu Thr Thr 1 5 97PRTArtificial SequenceSynthetic peptide
9His Asn Tyr Ala Arg Asp Cys 1 5 107PRTArtificial SequenceSynthetic
peptide 10Gln Lys Ala Thr Arg Thr Thr 1 5 117PRTArtificial
SequenceSynthetic peptide 11Arg Thr Asp Tyr Leu Val Asp 1 5
127PRTArtificial SequenceSynthetic peptide 12Tyr Asn Thr His Leu
Thr Arg 1 5 137PRTArtificial SequenceSynthetic peptide 13Gln Gly
Tyr Asn Leu Ala Gly 1 5 147PRTArtificial SequenceSynthetic peptide
14Glu Arg His His Leu Met Arg 1 5 157PRTArtificial
SequenceSynthetic peptide 15Gln Asn Ser Thr Arg Ile Gly 1 5
167PRTArtificial SequenceSynthetic peptide 16Tyr Asn Trp His Leu
Gln Arg 1 5 177PRTArtificial SequenceSynthetic peptide 17Leu His
His Gln Leu Val Arg 1 5 1867DNAArtificial SequenceSynthetic
oligonucleotide 18cttttatctg tcccctccac cccacagtgg ggccactagg
gacaggattg gtgacagaaa 60agcccca 671967DNAArtificial
SequenceSynthetic oligonucleotide 19tggggctttt ctgtcaccaa
tcctgtccct agtggcccca ctgtggggtg gaggggacag 60ataaaag 67
* * * * *